No retraction, correction or concern found when last checked on Oct 19, 2026.

Challenges of neuropathic pain: focus on diabetic neuropathy

Daniela C. Rosenberger, Vivian Blechschmidt, Hans Timmerman and 2 more

Journal of Neural Transmission · 2020 · Review · CC BY

Abstract

Neuropathic pain is a frequent condition caused by a lesion or disease of the central or peripheral somatosensory nervous system. A frequent cause of peripheral neuropathic pain is diabetic neuropathy. Its complex pathophysiology is not yet fully elucidated, which contributes to underassessment and undertreatment. A mechanism-based treatment of painful diabetic neuropathy is challenging but phenotype-based stratification might be a way to develop individualized therapeutic concepts. Our goal is to review current knowledge of the pathophysiology of peripheral neuropathic pain, particularly painful diabetic neuropathy. We discuss state-of-the-art clinical assessment, validity of diagnostic and screening tools, and recommendations for the management of diabetic neuropathic pain including approaches towards personalized pain management. We also propose a research agenda for translational research including patient stratification for clinical trials and improved preclinical models in relation to current knowledge of underlying mechanisms.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1Numerous reviews have been written about neuropathic pain (NP) in general (see, e.g., Baron; Campbell and Meyer; Colloca et al.; Meacham et al. ) and painful diabetic neuropathy (pDN) in particular (see, e.g., Feldman et al.; Nawroth et al.; Sloan et al. ). Many of them gave insight into recent findings on mechanisms of NP that may help to understand and further develop strategies for correct diagnosis and successful treatment. Although screening and diagnostic tools have become more and more available (Haanpaa et al. ), NP is considered to be an underdiagnosed condition because a clear, comprehensive classification has been lacking until recently (Finnerup et al. ). NP is no longer called “chronic intractable pain”, but its management remains difficult: with current pharmacologic concepts that are internationally recommended by guidelines, only 30% of patients experience a pain reduction of about 30% (Finnerup et al. ). The aim of this paper is to review mechanisms, assessment, classification, and management of peripheral NP. We will also discuss to what extent these underlying mechanisms have been considered in the development of diagnostic or treatment strategies in patients with painful (pDN) and painless diabetic polyneuropathy (dPNP) and what has proven to be useful. Given the importance as a global burden and rising number in patients as one of the main causes of NP (Rice et al.; IDF Diabetes Atlas; van Hecke et al. ), the main focus will be on pDN due to its high and increasing prevalence.

Definitions

2According to the taxonomy of the International Association for the Study of Pain (IASP 2011; Loeser and Treede ), neuropathic pain (NP) is defined as “pain caused by a lesion or disease of the somatosensory nervous system”. The definite diagnosis of NP requires a demonstrable underlying lesion or disease satisfying established neurological diagnostic criteria (Finnerup et al.; Loeser and Treede; Treede et al. ). Painful diabetic neuropathy (pDN) is a frequent subtype of peripheral NP; it is defined as “pain as a direct consequence of abnormalities in the peripheral somatosensory system in people with diabetes” (Jensen et al.; Tesfaye et al. ).

3IASP taxonomy differentiates NP from nociceptive pain and—more recently—nociplastic pain. Nociceptive pain describes “pain through activation of nociceptors in non-neural tissues by actual or threatened tissue injury”, while nociplastic pain is defined as “pain that arises from altered nociception despite no clear evidence of actual or threatened tissue damage causing the activation of peripheral nociceptors or evidence for disease or lesion of the somatosensory system causing the pain” (IASP; Kosek et al.; Loeser and Treede ). This distinction is essential, as different underlying mechanisms explain different treatment targets and responses to drugs. However, patients may present a substantial overlap of neuropathic and nociceptive pain in the same areas, e.g., in low back pain, postsurgical pain or osteoarthritis; this overlap has been called “mixed pain” (Freynhagen et al. ). Patients with substantial overlap of neuropathic and nociplastic pain are likely to exist also, but there are no systematic studies yet.

Classification of neuropathic pain

4Neuropathic pain may be classified according to the underlying lesion or disease (Scholz et al. ) or according to the clinical phenotype (Vollert et al. ). While the clinical phenotype may be useful for future personalized NP management (see below), the 11th edition of the International Classification of Diseases (ICD-11) differentiates NP of peripheral and central origin, comprising nine typical conditions associated with persistent or recurrent pain (Scholz et al., Table 1). There are also extension codes for pain severity (combining intensity, distress, and disability), temporal characteristics and psychological or social factors, as well as a link to the International Classification of Functioning (ICF) (Scholz et al.; Treede et al.; Nugraha et al.; WHO Classification ). Generally, NP is considered to be chronic, as it either persists continuously or manifests with recurrent painful episodes and is usually not limited by the natural healing process or treatment of the underlying disease. The IASP classification of chronic NP for ICD-11 represents the first systematic classification to date of common painful neurological disorders; member states are expected to report health statistics to WHO according to ICD-11 from 2022 onward. Thus, pDN is classified as chronic NP (top /first-level diagnosis) of peripheral origin (chronic peripheral NP; second-level diagnosis), painful polyneuropathy (third-level diagnosis) (Scholz et al. ). From the clinical point of view, a physical examination is crucial to (1) link the patient’s pain to a lesion or disease of the somatosensory nervous system, (2) to distinguish the NP component from nociceptive pain, and (3) to distinguish the NP component from nociplastic pain.

Etiology

5Neuropathic pain may result from a broad range of diverse neurological disorders affecting the peripheral or the central nervous system (Table 2). Chronic pain may also occur in neurological conditions of unknown etiology, i.e., idiopathic neuropathies (Colloca et al. ). However, not all patients affected by neural disorders or lesions do develop NP. Extent and severity of NP vary markedly between patients suffering from the same underlying disease or neural lesions, particularly in diabetic polyneuropathy (dPNP) (Themistocleous et al. ). Whether or not patients develop NP seems to be a multifactorial interaction of psychosocial, genetic, biological, and clinical risk factors (Hebert et al. ). A large (~ 10,000 participants), currently running multi-center observational study, DOLORisk, aims to elucidate these risk factors of development of NP (Pascal et al. ).

Epidemiology

6Chronic NP frequently causes major suffering, a reduced quality of life and disability in patients, and is a major factor contributing to the global burden of disease (Doth et al.; Smith and Torrance; Alleman et al.; Rice et al. ). For the general population, a prevalence of NP of 6.9–10% is estimated (Bouhassira et al.; Attal et al. ). The prevalence of NP is likely to increase as we are facing, among other risk factors, an aging population, increasing obesity rates and an increase in survival of cancer patients that may suffer from sequelae of chemotherapeutics (Moulin et al. ). However, systematic registration of incidence and prevalence of NP in the general population is difficult because the current versions of the International Classification of Disease (ICD-9 or ICD-10) are focused on the underlying lesions or diseases and not on whether or not they are painful (Finnerup et al. ). Such data have only been obtained by dedicated surveys in certain countries or for certain etiologies (Colloca et al. ). Generally, the association of pain and the underlying neurological disease is highly variable. While in some diseases such as postherpetic neuralgia or trigeminal neuralgia, pain is the most prominent manifestation, in others such as chemotherapy-induced neuropathy or dPNP, it may occur only in a subgroup of patients (Table 3). Even among patients with the same underlying cause of NP, painful symptoms and signs may differ depending on the studied population, the diagnostic tools or criteria (Nawroth et al. ).

7Given the increasing prevalence of diabetes mellitus (DM) worldwide, dPNP is and will be one of the most important and common causes of NP. In 2000, 171 million (2.8% of the world population) people suffered from DM (Wild et al. ), projections at the time for 2030 of 366 million (4.4%) are already by far surpassed. Today, in 2019, 425 million (8.6%) are affected; in 2045 629 million (9.8%) people are expected with DM worldwide (IDF Diabetes Atlas; United Nations Revision of World Population Prospects). dPNP is a frequent complication of long-term diabetes and one of the leading causes of morbidity and disability. While up to 60% in patients with chronic DM are affected by dPNP, already in newly diagnosed patients, 7–10% suffer from neuropathy (Tracy and Dyck; Tesfaye; Abbott ). It seems to be generally more prevalent in Europeans as compared with Asians (Abbott et al. ). In dPNP, NP is one of the main symptoms. Mostly, patients suffering from pDN are regarded as a subgroup of dPNP patients (≤ 60%, Abbott et al. ). However, in one-fourth of all DM patients, painful symptoms occur without any other signs of neuropathy (Abbott et al. ). Of all DM patients, 20–50% suffer from pDN (Abbott et al.; Bouhassira et al.; Alleman et al.; Sloan et al.; Truini et al. ).

8The burden of disease in pDN is much higher than in other chronic pain conditions (Sadosky et al. ) resulting in reduced health-related quality of life (van Acker; Callaghan et al.; Smith et al.; Bouhassira et al.; Alleman et al.; Finnerup et al.; Finnerup et al. ): comorbidities, such as sleep disorders, anxiety/depression (Gore et al.; Jain et al. ) and cardiovascular diseases (Sadosky et al. ), and “severe” pain in more than half of the affected patients (Sadosky et al. ). Even 10-year mortality is higher in patients suffering from pDN than in patients without pain (Torrance et al. ).

Pathophysiology of peripheral neuropathic pain

9Neuropathic pain (NP) can be divided into central or peripheral syndromes, depending on the site of lesion or underlying disease. This section focuses on conditions that are considered consequences of a peripheral insult. Central NP conditions are less well understood and might differ in their underlying mechanisms, so they need separate consideration (Watson and Sandroni ).

10Peripheral nerve damage provokes persistent maladaptive structural and functional responses in the somatosensory system. Therefore, peripheral NP results from both, peripheral and central mechanisms. Clinical signs include sensory loss, spontaneous (ongoing) pain and hypersensitivity, including allodynia and hyperalgesia (evoked pain) (Jensen and Finnerup ).

11Most of the current ideas regarding the pathophysiology of NP have been derived from animal models of mechanical nerve damage, such as spared nerve injury (SNI), chronic constriction injury (CCI), and spinal nerve ligation (SNL). Additionally, pathogenesis of NP has also been studied in rodent models of diabetes, chemotherapy, herpes zoster and HIV–peripheral neuropathy (Colleoni and Sacerdote ). These preclinical studies delineated a series of mechanisms along the entire nervous system (Fig. 1). In the peripheral nervous system (PNS), nerve damage leads to reduced signal transmission to the spinal cord and alterations in gene expression patterns and ion channel properties leading to ectopic activity. In the central nervous system (CNS), enhanced synaptic transmission and disinhibition at the spinal, thalamic and cortical level lead to amplified central processing. Human studies revealed some of these mechanisms in patients with NP and in human surrogate models of NP (Binder; Klein et al.; Vollert et al. ). In the following sections, a short overview of these mechanisms is given to understand current and future strategies for the assessment and treatment of NP.

Mechanisms of sensory loss

12After peripheral nerve injury, neurodegeneration disrupts the connection between the periphery and the CNS, ultimately resulting in sensory loss. After transection of axons of primary sensory neurons, the distal axons die due to Wallerian degeneration (Campbell and Meyer ), particularly affecting small-fiber neurons including nociceptors (Tandrup et al. ). Later on, persistent aberrant afferent input may provoke the degeneration of superficial dorsal horn neurons via glutamate-mediated excitotoxicity (Scholz et al. ). Neuroimaging studies in patients with NP hint that neurodegeneration may also occur in the brain (May ).

Mechanisms of ongoing pain

13Meanwhile, the proximal remnants of the fibers (e.g., C-fibers) at the injury site can generate ectopic activity and so pain originates from an area with reduced sensitivity to thermal and mechanical stimuli. Microneurographic recordings of single C-fibers have demonstrated spontaneous activity in human studies investigating several NP syndromes (Serra et al. ). Ongoing pain, such as burning ongoing pain and spontaneous shock-like pain, is the most prevalent feature and most troublesome clinical sign in NP syndromes (Gold and Gebhart ). Since ongoing pain can be temporarily abolished by blocking peripheral input, research focuses on the primary afferent fiber as the origin of ongoing pain (Gracely et al.; Haroutounian et al. ). Ongoing pain is thought to result from ectopic action potential (AP) generation within the nociceptive pathways through enhanced synaptic transmission to the spinal neurons and/or enhanced intrinsic excitability of second-order neurons (Woolf et al.; Balasubramanyan et al.; Hains and Waxman ). Ectopic discharge was originally described as arising only at the site of the nerve lesion (Wall and Gutnick ), but can occur at multiple sites, including the site of injury, along the axon and in the dorsal root ganglia (DRG) of nociceptors (Devor ). Enhanced sensitivity of primary sensory neurons to endogenous thermal and chemical stimuli may also cause spontaneous pain.

14Ectopic discharge is associated with increased expression of voltage-gated sodium channels (VGSC) in primary afferents (Cummins et al. ). Clustering of VGSC might lower the action potential (AP) threshold at sites of ectopic impulses resulting in hyperexcitability (Lai et al. ). In peripheral sensory neurons, the VGSC subtypes Nav1.7, Nav1.8, and Nav1.9 are particularly prevalent. Their contribution to pain pathogenesis varies in different NP conditions (Dib-Hajj et al.; Hameed ). Rare inherited channelopathies show a crucial role of VGSC in pain processing (Bennett and Woods; Hoeijmakers et al. ); loss-of-function mutations in Nav1.7 are associated with insensitivity to pain (Cox et al. ), while gain-of-function mutations in Nav1.7 lead to hyperexcitability and pain disorders in humans, erythromelalgia and paroxysmal extreme pain disorder (Estacion et al. ). Neurotrophic factors induce alterations in the VGSC, e.g., time-dependent changes in Nav1.8 (Amir et al.; Coward et al. ), including upregulation, low excitability threshold and an increased suprathreshold ion current (Lai et al. ). Nav1.9 might also contribute to increased excitability in NP (Hoffmann et al. ). After nerve injury, large numbers of fast Nav1.3 are expressed, which otherwise are only present during embryonic development. Nav1.3 causes strong fluctuations of the membrane potential and is probably the cause of spontaneously arising AP bursts (Wood et al. ).

15Some NP conditions, however, are independent of VGSC (Minett et al. ). Apart from VGSC, some types of calcium channels (Zamponi et al. ), potassium channels (Busserolles et al. ), and hyperpolarization-activated cyclic nucleotide-gated channels (Chaplan et al. ) also contribute to hyperexcitability.

Peripheral nociceptor sensitization

16An important characteristic of nociceptors, such as unmyelinated (C) and thinly myelinated (Aδ) primary afferent neurons, is sensitization. Sensitization, which typically develops as a consequence of tissue injury and inflammation, is defined as a reduction in the threshold, an increase in the magnitude of response to noxious stimulation and spontaneous activity. The inflammatory processes in Wallerian degeneration may hence render the remaining intact fibers after nerve injury hyperexcitable (Campbell and Meyer ).

17The discovery of the transient receptor potential (TRP) family led to a better understanding of how nociceptors detect external stimuli and how they can be sensitized (Caterina et al. ). TRP channels are activated by various nociceptive physical and chemical stimuli, providing the generator potential to activate VGSC resulting in ectopic discharge (reviewed in Mickle et al. ). Proinflammatory mediators enhance TRPV1 channel function via phosphorylation, provoking peripheral sensitization. Sensitized TRPV1 gets activated by minimally acidic pH and at body temperatures, leading to sustained generator potentials and electrical discharge. Expression of TRPV1 can also be upregulated by nerve damage and the increased inflammatory microenvironment (reviewed in Mickle et al., ). Translocation of TRPV1 to the cell surface also increases the channel activity. Activation of TRPV1 results in membrane depolarization with subsequent AP generation via VGSCs; TTX-insensitive sodium channels can also be sensitized via phosphorylation by protein kinases A and C (Gold et al. ).

18Neural damage provokes highly organized neuroimmune interactions in peripheral nerves that play a key role in initiating many cellular mechanisms underlying persistent NP (reviewed in Costigan et al.; Marchand et al.; Scholz and Woolf ). Accumulation of infiltrating immune cells such as neutrophils, macrophages, and mast cells at the injured site contributes to peripheral sensitization in most neuropathic conditions (Ren and Dubner ). They release substances (e.g., NO, ATP, lipids prostaglandins, cytokines, etc.), which sensitize the remaining intact axons and contribute to axonal damage. Schwann cells secrete nerve growth factor (NGF) and matrix metalloproteinases (MMPs) that contribute indirectly to central sensitization (see below). Neuropeptides from nociceptive axons, kinins, and nitric oxide cause a local increase in blood flow and tissue swelling. This neurogenic neuroinflammation affects the micromilieu in the nerve. After the damaged nerves are removed by phagocytosis, neuropathic sensitivity is then maintained by intact axons. Remarkably, similar changes also occur in the dorsal root ganglion (DRG).

Spinal sensitization

19The IASP defines central sensitization as an “increased responsiveness of nociceptive neurons in the CNS to their normal or subthreshold afferent input” (Loeser and Treede ). The main reason for central sensitization in peripheral NP is the persistent nociceptive afferent input after peripheral nerve damage (Haroutounian et al. ). Blocking the afferent input, even in patients with profound signs of central sensitization, temporarily abolishes NP symptoms (Gracely et al. ). Patients with NP show different signs of central sensitization, including a pattern of hyperalgesia similar to secondary hyperalgesia (i.e., an increase in pain sensitivity outside the area of injury).

20Alterations in calcium permeability, gene expression patterns, phosphorylation of ion channels, neuronal plasticity, and the misbalance between descending facilitation and inhibition promote central sensitization (Latremoliere and Woolf ). In animal models of peripheral nerve injury, activation of several protein kinases leads to phosphorylation of ionotropic and metabotropic glutamate receptors and subsequently to enhanced excitatory postsynaptic potential frequency and amplitude (Choi et al.; Hildebrand et al. ). Ion channel alterations, such as upregulation of the α2δ-1 subunit of voltage-gated calcium channels (Luo et al. ), occur after peripheral nerve damage.

21Long-term potentiation (LTP), an activity-dependent persistent synaptic strengthening, intensively studied in the hippocampus, appears to play a role in spinal sensitization after noxious input (Ji et al.; Sandkuhler ). There is still no proof of LTP in NP patients, but there are several lines of evidence in favor: conditioning electrical stimulation of the same type that induces LTP in rodents has been shown to induce long-lasting amplification of pain perception in humans (Klein et al. ). Brief application of high-dose opioids reversed activity-dependent LTP at C-fiber synapses in preclinical studies (Drdla-Schutting et al. ). Further studies need to investigate whether inhibition of LTP can also outlast drug effects in NP patients, which would suggest reversal of LTP and hyperalgesia.

22Increased N-methyl-d-aspartate receptor (NMDAR) activity contributes to central sensitization after nerve damage. Activation of intracellular pathways by protein kinases leads to phosphorylation of NMDARs. Afterwards, NMDARs respond stronger to agonists. Under normal circumstances, NMDA receptor channels are blocked by Mg2+ ions. Phosphorylation by protein kinase C increases the opening probability and decreases the affinity of NMDARs for extracellular Mg2+ (Chen and Huang ). Activation of protein kinase C also facilitates the upregulation of NMDAR activity and enhances LTP (Lu et al. ).

23Activation of NMDARs boosts synaptic efficacy and causes Ca2+ influx, which can activate intracellular signaling pathways that initiate and maintain central sensitization. Targeting α2δ-1-bound NMDARs with gabapentinoids or α2δ-1 C-terminal peptides can attenuate nociceptive drive from primary sensory nerves to dorsal horn neurons in NP (Chen et al. ).

Involvement of microglia in spinal sensitization

24In the last decade, a growing body of literature has delineated neuronal interactions with non-neuronal cells and both their contributions to NP, particularly focusing on neurogenic neuroinflammation (i.e., inflammatory reactions in response to neuronal activity) (Xanthos and Sandkühler ). While most studies on diseases of the CNS focus on how microglial-driven neurodegeneration develops, pain researchers turned to investigate mediators released by microglia that modulate synaptic transmission (Salter and Stevens; Woolf and Salter ). Since the first role on the specific role of microglia in NP (Jin et al.; Raghavendra et al.; Tsuda et al. ), evidence has grown on the role of microglia in preclinical models of NP (Clark and Malcangio; Inoue and Tsuda; McMahon and Malcangio; Tsuda et al. ), the contribution of astrocytes is less clear. Since there is now great interest in targeting neuroinflammation to treat NP conditions, some of the neuronal microglial signaling pathways will be presented.

25Microglia, the macrophages of the CNS, are found massively in the dorsal horn close to central terminals of damaged afferents (Beggs and Salter ) soon after peripheral nerve injury. This activation is caused by several mediators acting on microglial receptors, e.g., ATP acting on P2X4 and P2X7 (Bernier et al.; Inoue; Tsuda et al. ) or the two chemokines fractalkine (CX3CL1) and CCL2 acting on their specific receptors (CX3CR1, CCR2) (Clark and Malcangio; Milligan et al.; Thacker et al.; Zhuang et al. ). Toll-like receptors are also involved in microglial activation (reviewed in Lacagnina et al. ). Subsequently, microglial phenotype changes from a surveillance state to an activated state and several intracellular signaling cascades are activated, e.g., phosphorylation of p38 mitogen-activated protein kinase (MAPK) (Jin et al. ). As a consequence, microglia release proinflammatory mediators such as tumor necrosis factor-alpha (TNF-alpha) (Schafers et al. ), interleukin 1β (IL-1β) (Gruber-Schoffnegger et al. ), and brain-derived neurotrophic factor (BDNF) (Coull et al. ) that establish a positive feedback loop during nociceptive signaling and modulate spinal neurons leading to enhanced synaptic transmission (reviewed in Ji et al.; Tsuda et al. ). Blocking microglial activation can prevent chronic pain, but cannot reverse it (Raghavendra et al.; Zhang et al. ).

26In humans, direct evidence of glial activation and its contribution to pain pathogenesis is scarce, but there is evidence of increased levels of proinflammatory mediators in cerebrospinal fluid (e.g., chemokines, TNF-alpha, IL-6) as well as low levels of the anti-inflammatory mediator IL-10 supporting the idea of central neuroinflammation in NP patients (Backonja et al.; Backryd et al.; Kotani et al.; Sun et al. ). Elevated levels of a neuroinflammation marker translocator protein (TSPO) with in vivo PET/MR imaging in patients with several chronic pain states including lumbar radiculopathy were demonstrated (Albrecht et al. ).

Supraspinal changes

27Hyperexcitability of neurons in nociceptive pathways (Patel and Dickenson ) and ion channel alterations (Shen et al.; Wang et al. ) can also be found in higher brain regions in NP. Ectopic discharge in the CNS following neuronal disinhibition has been suggested (Keller et al. ) and thalamic bursting discharge of patients with central NP may represent such ectopic activity (Lenz et al. ). Microglial activation occurs in the thalamus, sensory cortex, and amygdala of the nociceptive pathways after peripheral nerve damage (Taylor et al. ). This glial activation leads to enhanced synaptic plasticity in the primary somatosensory cortex, resulting in mechanical hypersensitivity (Kim et al. ). Cellular events occurring during glial activation in the periaqueductal gray may also promote descending facilitation during NP (Ni et al. ).

28Descending pathways from the anterior cingulate gyrus, amygdala, and hypothalamus modulate the spinal transmission via brain stem nuclei in the periaqueductal gray and rostroventral medulla involving neurotransmitters such as norepinephrine, serotonin, and endogenous opioids. Under physiological conditions, there is a balance between descending facilitation and inhibition with a predominance of inhibition. Descending inhibition is at least partly mediated by spinal interneurons that act pre- or postsynaptically at the synaptic transmission from primary afferents to dorsal horn neurons (Zeilhofer et al. ). Under pathological conditions, several mechanisms lead to reorganization in these pathways, including an altered transmembrane anion gradient (Keller et al. ), microglial-driven downregulation of potassium chloride cotransporters (Coull et al. ), loss of GABAergic interneurons (Moore et al.; Scholz et al. ), impaired noradrenergic inhibition (Rahman et al. ) and increased descending serotoninergic facilitation (Bee and Dickenson ).

29In human studies, conditioned pain modulation (CPM) gives insight into endogenous descending inhibition and facilitation (Gasparotti et al.; Kennedy et al.; Granovsky ). In healthy volunteers, inhibitory effects dominate. Studies comparing healthy volunteers with patients with peripheral polyneuropathy have demonstrated significantly impaired CPM in nondiabetic painful neuropathy (Tuveson et al. ) and in pDN patients (Granovsky et al. ). CPM can predict the success of pain therapy (Bosma et al.; Yarnitsky et al. ) and increasing CPM efficacy can also alleviate pain (Schuh-Hofer et al. ).

30Neuroimaging studies have shown multiple changes in activity and functional connectivity in CNS regions involved in pain processing and pain modulation (Moisset and Bouhassira ). To date, there is no agreement on whether central sensitization acts only as an amplifier of peripheral signals (Meacham et al. ) or as an independent pain generator in peripheral NP conditions (Ji et al. ). Nevertheless, central mechanisms are essential for the maintenance and chronification of NP (Latremoliere and Woolf ).

Assessment of peripheral neuropathic pain

31Neuropathic pain (NP) describes a group of syndromes with many different causes and varying clinical manifestations. Diagnostic algorithms differ depending on whether the underlying lesion or disease is in the peripheral or central nervous system. Hence, a first subdivision of NP is peripheral versus central NP (Scholz et al. ). The basic diagnostic approach (i.e., according to the grading system) is the same (Treede et al.; Finnerup et al. ), but assessment tools are different (e.g., punch skin biopsy for peripheral vs. MR imaging for central NP).

Grading system for neuropathic pain assessment

32The Neuropathic Pain Special Interest Group (NeuPSIG) of the International Association for the Study of Pain (IASP) issued diagnostic criteria for NP, the Neuropathic Pain Grading System, developed to determine the level of certainty that a patient’s pain is neuropathic in nature or has a neuropathic component in mixed pain syndromes (Finnerup et al.; Treede et al. ); it was intended to be used for clinical diagnostics as well as clinical research. This diagnostic approach was also included in the assessment guidelines for NP (Cruccu and Truini; Deng et al. ) and in ICD-11 (Scholz et al. ). The stepwise approach is based on the history of the patient, physical examination, and confirmatory tests (Table 4). The initial grading system (Treede et al. ) struggled with the paradox that classical trigeminal neuralgia is not associated with sensory deficits in the painful area, yet is one of the commonly accepted peripheral NP syndromes. When evoked paroxysms of trigeminal neuralgia had been re-conceptualized as sensory signs (Cruccu et al. ), the following hierarchical sequence of four steps could be established in the revised grading system (Finnerup et al. ):

33Step 1: The medical history of the patient needs to suggest a lesion or disease that is capable of causing NP. Step 2: Pain distribution is plausible for the underlying lesion or disease (according to, e.g., pain drawing of the patient). When these two conditions are met, the possibility of NP is considered possible (possible NP). A detailed clinical examination should then be performed to find confirmatory evidence for the pain distribution and the underlying lesion or disease. Step 3: Since there is no confirmatory test for the spatial extent of perceived ongoing pain, the spatial extent of sensory signs is used as a surrogate. If this condition is also met, the neuropathic nature of the pain is considered to be likely (probable NP). Step 4: Depending on the suspected lesion or disease, appropriate confirmatory tests are performed. When positive, they lead to the diagnosis of “definite NP”. The level “probable NP” is considered sufficient to initiate treatment. The level “definite NP” indicates that a physician is able to confirm that the patient has a neurological lesion or disease that might explain his/her pain (Finnerup et al. ).

34The steps in the grading system follow the usual algorithm of neurological diagnostics and are primarily based on clinical examination. Thus, the experience and skills of the physician who does the assessment are of importance and may be limiting. Most available guidelines agree with this, but applicability and usefulness for the day-to-day clinical setting are limited by test–retest reliability of clinical assessment (Cruccu and Truini; Deng et al. ). It should be noted that even the level ‘definite neuropathic pain’ does not mean that causality has been established; it refers to the fact that a physician is able to confirm that the patient has a neurological lesion or disease that might explain his/her pain (Finnerup et al. ). Lack of confirmation may, however, lead to underdiagnosing NP in patients with pain as their main or only symptom (Bouhassira and Attal; Cruccu et al.; Finnerup et al.; Scholz et al. ). The level “probable NP” is hence considered sufficient to initiate treatment.

Screening as a first step towards diagnosis

35Screening tools for NP are patient-reported questionnaires mostly based on pain descriptors or combined questionnaires and simple clinical tests (Table 5, see also Colloca et al.; Attal et al. ). They are widely used in daily clinical practice, especially by non-specialists to initiate necessary further diagnostic assessment (Haanpaa et al. ). They are also popular in clinical research due to their simplicity and low cost. Screening tools had different objectives when being developed, and validity is inconsistent, as different reference standards were used (old vs. current definition of NP). The value of a screening tool also depends on reliability, sensitivity for changes, usability in another language after thorough translation, and cross-cultural adaptation process.

36The DN4 has been validated in a population of patients with painful diabetic neuropathy (pDN) (Spallone et al. ), which was defined as “the presence of diabetic polyneuropathy plus chronic neuropathic pain in the same area as neuropathic deficits”; NP was assessed based on pain history and examination, which is consistent with the grading system. DN4 showed a sensitivity of 80% and a specificity of 92%. Another study compared the DN4 and the PainDETECT with the NeuPSIG definition and grading system as the reference standard; it resulted in a sensitivity and specificity for the DN4 of 88% and 93% and for the PainDETECT of only 61% and 92% (Themistocleous et al. ).

37In a recently published systematic review regarding measurement properties of different screening tools for NP it was concluded that the Neuropathic Pain Questionnaire (NPQ) (Krause and Backonja ) and the DN4 (Bouhassira et al. ) were the most suitable for use in daily clinical practice (Mathieson et al. ). However, screening tools developed before 2008 (e.g., PainDETECT; Freynhagen et al. ) were validated against an obsolete definition of NP (“dysfunction” instead of “lesion or disease”), but not against the current definition of NP as endorsed by NeuPSIG (Treede et al. ), IASP (Jensen et al. ) and WHO (Scholz et al. ). DN4 and PainDETECT correlate only moderately against the grading system (Timmerman et al.,; Epping et al.; Tampin et al. ). This might lead to inconclusive results in prevalence studies and inaccurate clinical diagnostics and hence, improper treatment. Therefore, screening cannot replace thorough physical examination (Timmerman et al. ).

Bedside examination for diabetic neuropathy and neuropathic pain

38Bedside examination (BSE) in patients with DM is essential when suspecting diabetic polyneuropathy (dPNP) and/or pDN. Most guidelines advise yearly screening for dPNP (in T1DM starting 5 years after diagnosis, in T2DM starting immediately after diagnosis; Pop-Busui et al.; German National Disease Management Guideline for Diabetic Neuropathy). A thorough clinical examination, including inspection of the feet, evaluation of sensory loss, arterial pulses, skin state, pain assessment, and BSE as described below is an advisable basis. For the vast majority of patients, the diagnosis of dPNP is based on history and examination, without further necessary testing.

39A typical BSE test in patients suspected for dPNP is the 128 Hz tuning fork (placed at the dorsum of the interphalangeal joint of the hallux) to examine vibration perception. It is a valid and reliable tool for screening purposes, manageable in daily clinical practice (Meijer et al. ). Additionally, testing by monofilaments is easily applicable and has a reliable outcome. Two studies (Olaleye et al.; Perkins et al. ) found the following BSE tests useful to differentiate between DM patients with and without neuropathy: The Semmes–Weinstein 10 g monofilament examination (SWME), the superficial pain sensation (via a sterile neurotip) and vibration (on–off method). Nerve Conduction Studies (NCS), often a reference standard versus screening instruments, were also suggested to be included in annual screening for dPNP (Perkins et al. ). However, there is some evidence that one test alone is not sufficient (Brown et al. ) and that NCS may be replaced by QST profiling (Kopf et al. ).

40BSE for pDN and NP, in general, should include a pain drawing by the patient (Hansson; Margolis et al. ) and mapping of regions of sensory disturbances using at least one thermal and one mechanical test stimulus (Timmerman et al.; La Cesa et al.; Haanpaa et al.; Bouhassira and Attal; Cruccu et al.; Haanpaa et al. ). According to the grading system, sensory changes should be documented within the painful region for grading of “probable NP”. For a review including a well-designed table giving an overview of negative and positive symptoms of NP, see Gierthmuhlen and Baron.

Confirmatory tests

41There are two types of confirmatory tests in the assessment of patients with NP: (a) tests that confirm the sensory changes and (b) tests that confirm the specific underlying lesion or disease of the somatosensory nervous system explaining the symptoms of the patient (Brown et al.; Finnerup et al.; Olaleye et al.; Perkins et al. ).

42A number of confirmatory tests to investigate somatosensory pathway function are available (Table 6 including a column with remarks on the application in dPNP). They can be divided into structural tests (nerve biopsy, punch skin biopsy, corneal confocal microscopy) and functional tests (quantitative sensory testing, neurophysiological techniques). These tests are used mostly in research settings or in the diagnostic workup of patients with an atypical clinical presentation (Feldman et al.; Tesfaye et al. ).

43For all confirmatory tests, reference values have to be adjusted for test site, age, sex, and population. For quantitative sensory testing (QST), multi-center reference data are available for different body regions in both sexes and a broad age range (Magerl et al.; Pfau et al.; Vollert et al. ). These reference data allow a transformation of a patient’s data into Z-scores with a standard Gaussian distribution (zero mean and unity variance), provided the examiner has calibrated herself or himself for about 20 healthy subjects (Vollert et al. ). There are also some reference data available for non-Caucasian populations (Gonzalez-Duarte et al.; Ezenwa et al. ). For NCS, each laboratory is usually required to generate its own reference data. Published reference data can only be used for a broad orientation since the techniques are not standardized well enough, e.g., a normative database from a mainly Western population (USA) was found not to be suitable for a Japanese population (Hirayasu et al. ).

44Importantly, note that also “objective” instruments such as skin biopsies do not necessarily relate to the pain complaint of the patient. Although assessment of intraepidermal nerve fiber density (IENFD) through skin biopsy is validated for diagnostics of small fiber neuropathies, including dPNP (Lauria et al.; Tesfaye et al. ), the correlation between IENFD and severity of NP in dPNP is still debated. A flooring effect of IENFD has been suggested (Cheng et al.; Shun et al.; Sorensen et al.; Themistocleous et al.; Truini et al. ).

45Finally, not every neuropathy in patients suffering from DM is a diabetic neuropathy. Dependent on clinical presentation, laboratory testing is advised to exclude differential diagnosis, such as thyroid disease, autoimmune disorders, infections (e.g., HIV), vitamin deficiencies (e.g., vitamin B12) or intoxications (e.g., alcohol). Thus, diabetic neuropathy is a diagnosis of exclusion (England et al.; Pop-Busi et al.; Ziegler et al. ).

General aspects

46Diabetes mellitus (DM) is a common disorder marked by persistent hyperglycemia and other metabolic disturbances, such as dyslipidemia. Increased glucose levels affect primarily cells that have a limited capacity to regulate their glucose intake, including vascular cells, Schwann cells, and neurons of the peripheral and central nervous systems. Consequently, hyperglycemia leads to largely intractable complications such as retinopathy, nephropathy, hypertension, and neuropathy. However, not all patients with DM develop diabetic polyneuropathy (dPNP). In prospective studies with diabetic patients, environmental risk factors for the development of neuropathy in type 1 (T1DM) (Tesfaye et al. ) and type 2 diabetes (T2DM) (Andersen et al. ) were investigated: They include poor glycemic control (for T2DM Pop-Busui et al. ) and common cardiovascular risk factors (e.g., hypertension, raised triglycerides, obesity, smoking). Genetic risk factors might also contribute to the pathogenesis of dPNP (reviewed in Prabodha et al. ).

47Peripheral diabetic neuropathy can present as several different patterns (see “Clinical presentation of painful diabetic neuropathy”). Damage primarily occurs in sensory neurons, resulting in positive symptoms (e.g., pain, paresthesias) and negative symptoms, such as sensory loss (e.g., numbness). The most common pattern is the distal symmetric polyneuropathy, which clinically presents as a neuropathy not only predominantly of the feet, but also of the hands, with a distal-to-proximal gradient of severity (Callaghan et al. ).

Pathogenesis of diabetic polyneuropathy

48Evidence of the pathogenesis of dPNP has accumulated over the past decades, delineating alterations in neurons, glia, immune cells and vascular cells in the progress of DM leading to loss of peripheral nerve function (Fig. 2; reviewed in Feldman et al.; Feldman et al.; Schreiber et al.; Sloan et al.; Yagihashi et al. ). Many metabolic and vascular maladaptive responses have been described. Recently, the research focus turned to uncover interactions with Schwann cells and other non-neuronal cells, endoplasmatic reticulum stress, neurodegeneration, and mitochondrial dysfunction.

49Most data were obtained in preclinical studies investigating animal models of T1DM (streptozotocin) and less so of T2DM using diet or genetically induced DM (reviewed in O'Brien et al.; Sullivan et al. ). These animals develop primarily distal axon loss, systemic injury of the peripheral nervous system and altered interactions with Schwann cells, which is recognized as a model for dPNP.

50Evidence supports that the entire primary sensory neuron is targeted by diabetes. However, it remains elusive whether damage first targets peripheral axons and their associated Schwann cells or the neuron perikarya that reside in the dorsal root ganglia (DRG) where they are not protected by a blood–nerve barrier. Although dPNP is not considered primarily a demyelinating neuropathy, Schwann cells are targeted by chronic hyperglycemia and more severe cases of dPNP in patients include features of demyelination (Feldman et al.; Kobayashi and Zochodne ).

51Hyperglycemia and dyslipidemia are key players in the development of dPNP. This substrate overload leads to the accumulation of toxic metabolites and mitochondrial dysfunction, promoting metabolic, and oxidative stress and axonal degeneration (Fernyhough; Fernyhough and McGavock ). Glucose excess leads to polyol and hexosamine pathway hyperactivity, resulting in both increased reactive oxygen species (ROS) and inflammation, adding to mitochondrial injury (Feldman et al. ). Moreover, glycation of numerous structural and functional proteins leads to the production of advanced glycation end-products (AGEs). AGEs result in altered or loss of protein function and interact with AGE-specific receptor modifying gene expression, intracellular signaling, and promoting the release of pro-inflammatory molecules and free radicals (Singh et al. ). More recently, researchers have focused on dyslipidemia in mediating additional inflammation and ROS accumulation with continued and progressive nerve injury.

52Microvascular alterations induce impaired nerve perfusion provoking hypoxia and loss of nerve function (Tesfaye et al. ). Increases in endoneurial capillary density are present in diabetic patients, suggesting that capillary density may respond to diabetes-induced nerve ischemia (Thrainsdottir et al. ). Furthermore, altered bioavailability of different mediators including insulin growth factors, vascular endothelial growth factor (Schratzberger et al. ) as well as gasotransmitters (e.g., NO, CO, H2S) (van den Born et al. ) contributes to both vascular disease and neuropathy in diabetes.

53Although neurotrophic effects of insulin on sensory nerves have been shown (Frazier et al. ), correcting hyperglycemia with insulin has little effect on dPNP in patients with T2DM. By contrast, in T1DM patients with dPNP, normoglycemia through insulin treatment provides a substantial therapeutic benefit (Grote and Wright ). Inflammatory processes may be relevant, especially in the onset of dPNP and in developing pDN (Herder et al.; Magrinelli et al. ).

Painful vs. painless diabetic neuropathy

54Only about 20–50% of patients with DM and about 60% of dPNP patients develop NP. The reason why some patients experience NP while others do not is not fully understood. However, there has been growing evidence on risk factors (demographic, metabolic, sensory, genetic) for developing NP in dPNP (Shillo et al. ). Large, well-characterized, cross-sectional cohort studies have given valid insights into risk factors (Fig. 3) and somatosensory profiles of pDN. However, longitudinal studies are lacking.

55NP in dPNP seems to be associated with the female gender (Truini et al. ), increasing age (Van Acker et al. ), and ethnicity (Hebert et al. ). Metabolic issues including obesity (Ziegler et al. ), elevated HbA1c (Themistocleous et al. ), high alcohol intake, duration, and type of DM, might increase the risk of developing NP. The sensory phenotype and neuropathy severity are also associated with pDN (Raputova et al. ). Genetic variants (Blesneac et al.; Prabodha et al. ) and genetic variability are likely to interact with the environment to determine the risk of developing pDN.

Peripheral mechanisms of painful diabetic neuropathy

56For long time, it has been known that microvascular alterations, such as structural and functional abnormalities of the vasa nervorum (Cameron et al. ) and altered regulation of peripheral blood flow (Archer et al. ) are associated with pDN. More recently, dysregulation of the local blood flow in the skin, involving hypoxia-induced factor 1-alpha (Quattrini et al. ) and von Willebrand factor (vWF) (Shillo et al. ), has been found to contribute to NP. NP-related behavior has been found to be related to numerous metabolic pathways. There is limited evidence to support glycemic control or lifestyle modifications in reducing NP (Pop-Busui et al. ). Preclinical studies indicate that vitamin D plays a critical role in nerve function in health and possibly in NP syndromes (Fukuoka et al. ). Vitamin D levels have been found to be significantly lower in patients with painful compared to painless diabetic neuropathy (Shillo et al. ).

57There might be a special role for methylglyoxal (MGO) in pDN. In rodent models of pDN, MGO induced signs of hypersensitivity via activation of the sodium channel Nav1.8 and transient receptor potential channel ankyrin 1 (TRPA1) (Bierhaus et al.; Huang et al. ). MGO induces pain, axon-reflex-erythema, and long-lasting hyperalgesia via the activation of C-nociceptors in healthy humans. TRPA1 is crucially involved in MGO-induced pain sensation and heat hyperalgesia (Dull et al. ).

Central mechanisms of painful diabetic neuropathy

58Studies of the CNS demonstrate clear differences in painful compared to painless diabetic neuropathy. Spinal, somatomotor, limbic, thalamic, ascending, and descending modulatory systems demonstrate structural and functional alterations (Tesfaye et al. ). Changes in higher brain centers are also described in patients with pDN: cortical atrophy within the somatomotor cortex and insula (Selvarajah et al.; Shillo et al. ), abnormal cortical interactions within the somatomotor network (Selvarajah et al. ), and increased cerebral blood flow in the anterior cingulate cortex (Watanabe et al. ). It is still unknown whether the described CNS changes are only a response to afferent input of the peripheral nervous system or a primary mechanism responsible for the maintenance of pDN.

Clinical presentation of painful diabetic neuropathy

59Painful diabetic neuropathy (pDN) is defined as “pain arising as a direct consequence of abnormalities in the peripheral somatosensory system in people with diabetes” (Tesfaye et al. ). According to this guideline, pDN is diagnosed if pain lasted ≥ 3 months has a history of confirmed dPNP and an association with abnormal sensory signs of small fiber and large fiber neuropathy in a neuro-anatomically plausible distal and symmetrical distribution. The stepwise procedure (Table 4) consisting of a history of disease, examination, and confirmatory testing should also be pursued in patients with a suspected pDN.

60Distribution of both pain and sensory changes should be mapped (Cruccu et al.; Hansson; Margolis et al. ). The sensory changes are usually in a distal, symmetrical distribution (stocking or glove like): decreased sense of vibration, impairment of proprioception, reduced or even absent reflex activity in the Achilles tendon and diminished muscle strength or atrophy of the foot muscles, which might lead to pes cavus or hammertoes (Dyck et al.; England et al.; Martin; Peltier et al. ). However, in pDN, symmetrical, distal pain or numbness may also be the only indicative factors (Tesfaye et al. ).

61Paradoxically, lesions or diseases affecting the somatosensory nervous system do not only lead to a loss of function, but also to overexcitability and increased sensitivity to painful stimuli (hyperalgesia), pain sensations to normally non-painful stimuli (allodynia) and spontaneous pain. pDN patients often describe a prickling, burning, deep aching, sharp, stabbing, and/or electric pain. Signs of sensory gain were traditionally thought to be rare in pDN, but recent studies using QST demonstrated a high prevalence of mechanical hyperalgesia in pDN (Themistocleus et al.; Vollert et al.; Kopf et al. ). Preserved small fiber function combined with thermal hyperalgesia (“irritable nociceptor” phenotype) is much less frequent in pDN (< 10%) than in postherpetic neuralgia, where it was originally described (Fields et al.; Baron et al.; Edwards et al.; von Hehn et al. ). In most pDN patients, sensory loss of small and large fibers is pronounced (“deafferentiation” phenotype), while deep tissue mechanical pain (assessed by pressure pain threshold) is relatively intact (Themistocleous et al.; Baron et al.; Vollert et al. ).

62Small fiber neuropathy in DM may also lead to autonomic nervous system deficits in addition to cutaneous sensory loss and pain. Clinicians need to keep an eye on the usually slower developing autonomic diabetic neuropathy, which affects the cardiovascular, gastrointestinal or genitourinary system (Edwards et al. ) and is important for prognosis. In some cases, diabetic neuropathy with neuropathic symptoms may manifest even before DM has been diagnosed (Tesfaye et al. ), making diagnostics difficult.

Management of diabetic neuropathy

63Currently, there are three main elements in the management of diabetic polyneuropathy (dPNP): glycemic control, foot care, and symptomatic treatment, and predominantly pain therapy.

Glycemic control

64While diabetes is defined by increased glucose levels and tight glycemic control has a high value in its treatment, it is currently recommended to individualize glycemic control in patients with T2DM considering the benefit/risk ratio (Rodriguez-Gutierrez et al.; Qaseem et al. ). Hyperglycemia is not the prime driving cause of all complications (Tesfaye et al. ). Otherwise, diabetic complications including dPNP could be easily prevented and symptoms should be reduced by efficient glycemic control (Stolar ). While there is convincing evidence that enhanced glucose control significantly reduces or delays the incidence of developing clinical neuropathy in T1DM (Fullerton et al.; Albers et al. ), the data in the more frequent T2DM remain elusive (Pantalone et al.; Callaghan et al.; Ismail-Beigi et al.; Calles-Escandon et al.; UKPSD Study Group ).

65Comparing the effect of glycemic control, Callaghan and colleagues proposed that mechanisms of dPNP in T1DM and T2DM are fundamentally different, which should be considered in its treatment (Callaghan et al. ), still, a recent cohort study emphasizes that early, intensive glycemic control may be necessary to avoid diabetic complications and mortality (Laiteerapong et al. ). Interestingly, aggressive glucose control not only significantly increases the risk of severe hypoglycemic episodes (Callaghan et al. ), but can also result in treatment-induced neuropathy if glycemic control is achieved too quickly and to too low glucose levels (Gibbons,; Hwang and Davies ). It is suggested that neurons take up much more glucose than other cell types and, therefore, are more vulnerable to hypoglycemia (Low and Singer; Gibbons and Freeman ).

Foot care

66dPNP is the primary risk factor for the development of foot ulcers, increasing devastating outcomes of ulcerations that risk amputations (Ahmad; Boulton ). Management includes patient education, plantar pressure relief with orthoses and appropriate footwear, regular skin, nail and ulcer care (e.g., paring of calluses, debridement of infected or nonviable tissue) (Pinzur et al.; Kavitha et al. ).

Management of neuropathic pain and painful diabetic neuropathy

67Management of neuropathic pain (NP) in general and painful diabetic neuropathy (pDN) in particular is a challenge. A number of clinical practice guidelines, e.g., by the International Association for the Study of Pain (IASP) (Finnerup et al.; Dworkin et al.; Haanpaa et al. ), the European Federation of Neurological Societies (EFNS) (Attal et al.; Cruccu et al. ), the National Institute for Health and Care Excellence of the UK (NICE; Tan et al. ), the Canadian Pain Society (CPS; Moulin et al. ), the German Society for Neurology (DGN) and German National Disease Management Guideline for Diabetic Neuropathy have been published to facilitate assessment and management of NP also in patients with DM. Management rests on three pillars: management of diabetes, management of diabetic neuropathy, and symptomatic treatment of NP.

68Between these guidelines, there is broad agreement regarding pharmacological management of NP (Finnerup et al.; Deng et al.; Cruccu and Truini ).All guidelines strongly recommend three drug classes for first-line therapy of nearly all described syndromes: tricyclic antidepressants (particularly amitriptyline), serotonin–norepinephrine reuptake inhibitors (SNRIs; e.g., duloxetine) and calcium channel alpha-2-delta ligands gabapentin and pregabalin.Second-line recommendations by most guidelines (NICE: only rescue therapy because of higher withdrawal due to adverse events and weak study evidence) is tramadol (weak opioid + SNRI).Third- and fourth-line treatments commonly include strong opioids, anti-convulsants (other than gabapentinoids), and cannabinoids.

69All guidelines strongly recommend three drug classes for first-line therapy of nearly all described syndromes: tricyclic antidepressants (particularly amitriptyline), serotonin–norepinephrine reuptake inhibitors (SNRIs; e.g., duloxetine) and calcium channel alpha-2-delta ligands gabapentin and pregabalin.

70Second-line recommendations by most guidelines (NICE: only rescue therapy because of higher withdrawal due to adverse events and weak study evidence) is tramadol (weak opioid + SNRI).

71Third- and fourth-line treatments commonly include strong opioids, anti-convulsants (other than gabapentinoids), and cannabinoids.

72Depending on the syndrome, there are some specific recommendations, such as carbamazepine for trigeminal neuralgia or topical agents such as dermal patches releasing lidocaine or capsaicin and subcutaneous injection of botulinum toxin for localized NP (Mick et al.; Allegri et al. ). HIV-related NP is more refractory to pharmacotherapy than other types of NP (Finnerup et al. ). Opioids should be reserved for patients not responding to therapeutic alternatives because their long-term use carries a high risk of adverse effects and they are effective in the long run only in a small number of patients (for those patients, they may be a valuable element of their multimodal pain management). Nonsteroidal anti-inflammatory drugs have no proven efficacy against pain of purely neuropathic origin; however, they can be useful in mixed pain syndromes (Vo et al. ).

73The latest NeuPSIG guidelines (IASP) are based on a large meta-analysis, including unpublished trials (Attal and Bouhassira; Finnerup et al.; Cruccu and Truini ). These guidelines do not focus on etiologies, but treat NP as a specific entity because the efficacy of systemic treatments seems not to be affected by etiology. This unifying concept has been adopted by EMA for licensing of medications in Europe and is represented in Table 7. The FDA, however, still requests two independent studies per indication for licensing in the U.S.A. Depending on the country, some drugs have not been tested or approved for NP of certain underlying diseases; this needs to be verified locally before following any of these guidelines (Finnerup et al.; Attal et al.; Cruccu et al.; Haanpaa et al.; Dworkin ).

74Although NP is no longer considered chronic intractable pain, meta-analyses and systematic reviews on NP indicate that only a minority of patients have an adequate response to drug therapy (Baron et al.; Tan et al.; Finnerup et al.; Bril et al.; Moulin et al.; Scholz et al. ). Only one-third of pDN patients experience satisfying pain relief; the same is found for other patients with NP (Jensen et al. ). Mostly, complete freedom of pain cannot be achieved; however, improvement of life quality, sleep, social activities and ability to work is possible, which should be addressed in patient education (Baron and Binder; Finnerup et al. ). In clinical practice, combination pharmacotherapy is often applied, although the evidence for guiding such combinations is weak (Gilron and Jensen; Chaparro et al. ). In individual patients, second- or third-line medications may be more effective than medications coming out as first-line treatment from clinical trials. Thus, the management of patients with pDN or NP has to be on an individual basis. Non-pharmacological approaches and a generally multidisciplinary management of NP, including physical and psychological therapy and interventional approaches, need to be considered earlier (Finnerup et al.; Scholz et al.; Dworkin et al.; Torrance et al. ).

Outlook: individualized therapy of painful diabetic neuropathy

75Like in other fields of medicine, sex differences and genotype are thought to play a role in predicting treatment responses in pDN and NP (Zorina-Lichtenwalter er al; Belfer and Dai, van Hecke et al. ). Genetic factors may increase the risk of developing NP and predict the response to drugs with different mechanisms of actions (Dworkin et al.; Spallone ). So far, these factors do not play a role in designing the individualized treatment plans for patients with pDN or NP in general.

76Another approach to identify possible responder populations is stratification according to the sensory phenotype of the patients, e.g., according to their QST profile or conditioned pain modulation (CPM) (Attal et al.; Baron et al.; Treede ). Recent multicenter clustering studies using QST parameters in patients with NP of different origins identified three subgroups (sensory loss, thermal hyperalgesia, and mechanical hyperalgesia; Vollert et al. ). Stratifying patients according to their underlying distinct mechanisms may help to decrease NNTs (Baron et al. ), e.g., NNT of oxcarbazepine differed between 3.9 in the irritable and 13 in the non-irritable nociceptor phenotype (Demant et al. ). Clonidine significantly reduced foot pain associated with pDN in a subgroup of patients with a preserved nociceptor function screened using 0.1% capsaicin (Campbell et al. ). Patients with pDN with a less efficient CPM, reflecting a malfunctioning pain modulation by the monoaminergic descending pathways, showed a better efficacy of duloxetine treatment (Yarnitsky et al. ).

77Stratification according to patient-reported questionnaires such as NPSI or painDETECT seems promising (Forstenpointner et al.; Bouhassira et al. ). Studies analyzing patterns of sensory symptoms found that classification based on the symptom clusters was more appropriate than based on etiology (Attal et al.; Baron et al. ). In spite of the recent progress towards an individualized mechanism-based pain therapy based on the sensory phenotype, which may reflect differences in underlying mechanisms, more research is needed before personalized medicine can reach pDN patients.

Research agenda

78Although considerable research has been devoted to uncovering mechanisms of painful diabetic neuropathy (pDN) and neuropathic pain (NP) in general, treatment options to eliminate the root causes are still lacking. The research agenda for mechanism-based treatment of NP proposed in 1990 is still valid (Max ): “The identification of more effective, less toxic treatments that can be individualized to patients with particular underlying mechanisms requires several coordinated research approaches:development of drugs that correct particular pathophysiological mechanisms in animal models of neuropathic pain;delineation of classifications of neuropathic pain patients that correspond to the underlying pathophysiology of their pain;clinical trials designed to cull out specific subsets of patients responding to a particular treatment.”

79development of drugs that correct particular pathophysiological mechanisms in animal models of neuropathic pain;

80delineation of classifications of neuropathic pain patients that correspond to the underlying pathophysiology of their pain;

81clinical trials designed to cull out specific subsets of patients responding to a particular treatment.”

Pharmacological targets

82Current therapeutic strategies for NP, in general, aim to reduce the excitability of neurons in the peripheral and central nervous system by modulating the activity of ion channels (e.g., application of lidocaine and capsaicin), by modulating synaptic transmission (e.g., gabapentinoids) or by mimicking and enhancing endogenous inhibitory mechanisms (e.g., tricyclic antidepressants, duloxetine, and opioids). However, there is still a large gap between theoretically effective target mechanisms and actual efficacy in clinical studies.

83After the discovery of complete insensitivity to pain in patients with null mutations in the sodium channel Nav1.7 (Cox et al. ), both academia and industry have worked intensively on specific Nav1.7 inhibitors. Until now, there has been no successful clinical trial on pain relief due to targeting selectively Nav1.7, which demonstrates the difficulties of the translation of the even most compelling targets into therapeutics. Lacosamide has a certain preference for Nav1.7, but is licensed only for the treatment of epilepsy in spite of some evidence for efficacy in pDN (Rauck et al.; Wymer et al. ).

84Considering the role of immune cells and glia in the development of NP, there has been great interest in therapeutically targeting neuroinflammation. However, most of the broad array of compounds (reviewed in Mika ) that successfully inactivate or disrupt glial function and attenuate pain-responsive behavior in animal models of NP are inappropriate for human application. Minocycline, a commonly used second-generation tetracycline antibiotic and non-specific blocker of microglial activation, demonstrated very promising results in the reduction of NP in preclinical studies. However, the efficacy of minocycline in clinical trials was disappointing (Martinez et al.; Vanelderen et al.; Sumitani et al.; Curtin et al. ). Metformin, an oral antidiabetic used to treat T2DM, reduces microglia surrounding sensory neurons in the spinal cord and blocks neuropathic hypersensitivity in male mice, but seems to worsen the situation in females (Inyang et al. ). Sex differences in the role of microglia in NP mechanisms (more predominant role in male rodents) have recently dampened enthusiasm for this treatment target (North et al.; Sorge et al. ).

85Targeting metabolic and inflammatory alterations in diabetic polyneuropathy (dPNP) has been promising in preclinical animal models (reviewed in Dewanjee et al., Edwards et al. ). The clinical translation, however, is challenging. Currently, glycemic control and improved lifestyle remain the only disease-modifying therapies for dPNP. Benfotiamine, targeting the hexosamine pathway (Sanchez-Ramirez et al.; Stracke et al. ), actovegin, improving tissue glucose and oxygen uptake (Ziegler et al. ) and the antioxidant alpha-lipoic acid (Papanas and Ziegler; Ziegler et al.; Ametov et al. ) are some of the very few strategies that lead to pain reduction in pDN patients in clinical trials among pathogenesis-oriented treatment of dPNP. However, none of them is currently approved and most of the strategies that succeeded in preclinical studies were either not tested in humans or failed in clinical trials (Dewanjee et al.; Chalk et al.; Grewal et al. ). Failure has been attributed to trial design and the inability to reach therapeutic plasma levels without toxic side effects. However, there is still extensive preclinical research on further mechanisms and new targets ongoing.

86For the management of NP in general, prospective targets include several intracellular signaling pathways (Khangura et al. ). For dPNP and pDN in particular, recent strategies have also addressed modulating well-known targets with new pharmaceuticals, e.g., lacosamide, fulranumab and mirogabalin (Wymer et al.; Rauck et al.; Wang et al.; Vinik et al. ).

Preclinical models

87One key factor for the successful clinical translation is choosing the adequate preclinical animal models of the disease and adequate outcome measures (Gregory et al.; St John Smith ). The most frequently used rodent models look at the effects of partial mechanical nerve damage using reflex measures of stimulus-evoked pain; these models exhibit a similar sensory phenotype as peripheral nerve injury in humans (Gierthmuhlen et al. ), but bear poor resemblance to the clinical appearance of most NP patients.

88Models that try to resemble human pDN (Gao and Zheng ) include high-dose streptozotocin that is toxic to pancreatic insulin-secreting β-cells and genetically modified strains are used to mimic the metabolic phenotype of T1DM. There are genetic and diet-induced animal models available to investigate NP in T2DM. However, currently, no single rodent model accurately mimics human pDN (O’Brien et al. ).

89Moreover, the difference in pain assessment is a major problem: patients with NP primarily suffer from ongoing pain that is independent of external stimuli that is hard to measure in rodents (Tappe-Theodor and Kuner ). Current approaches assess pain-induced changes in gait (dynamic weight-bearing), housekeeping (burrowing), exploratory behavior (elevated plus maze, open field) or learned helplessness (forced swim test, tail suspension test).

90Most knowledge about mechanisms of dPNP, pDN, and NP was gained in genetically homogenous male rodents, while patients vary in sex, ethnicity and genetic background, age, and duration of the underlying disease. To make future preclinical studies more predictive for the clinical situation, several design parameters should be expanded: (1) the wide variety of potential underlying lesions or diseases of NP suggests that a variety of models should be studied. (2) Multiple endpoints should be assessed including measures of both evoked and ongoing pain. (3) Comorbidities and quality of life should be assessed. (4) Animals with genetic variability should be used, e.g., outbred strains. (5) Studies should be done in male and female animals.

Clinical trial design

91Another key factor for a better clinical translation of preclinical studies is an improvement in clinical trial design. Compared with fields like oncology or infectious diseases, clinical trials on treating pain conditions can be quite primitive in assuming that all pain is one and the same. In the presence of evidence for multiple distinct mechanisms of pain generation, it is necessary to shift paradigms towards more specific mechanism-based indications. Clinical practice is moving towards individualized pain management, so it is advisable for the pharmaceutical industry to move in the same direction and supply the necessary specific analgesics. The European Medicines Agency published guidelines on how to conduct trials for the development of pharmaceutics for pain therapy. This guideline encourages stratification according to the phenotype (QST profile or CPM, including assessment of stimulus-evoked pain) of the patients as a first step to identify possible responder populations for existing or future medication (Cruccu and Trunini; Attal et al.; Baron et al.; Baron et al; Treede ). As in preclinical studies, clinical trials should include participants of both sexes, with appropriate precautions for women of childbearing age. After all, women are more frequently affected by NP than men. Finally, pain intensity as a primary endpoint should be replaced by pain severity, which is a combination of pain intensity, distress, and functional impairment (Treede et al. ).

Conclusion

92Treatment of NP, in general, and pDN, in particular, is challenging. Treatment of the underlying lesion or disease has been stated as a goal of NP management. This may sound manageable for dPNP via glycemic control, but clinical experience indicates that this concept holds only for T1DM, but less so for T2DM. Moreover, treating the neuropathy does not always alleviate the pain. Therefore, there is a continuing need for better analgesic medications for pDN and NP. Clinically, the field moves towards individualized pain management, which necessitates a mechanism-based pharmacotherapy of pDN. For this purpose, predictors and biomarkers need to be validated for both clinical trials and clinical practice. Several candidates have already been proposed (genetics, sex, sensory phenotype), so significant progress is expected to be made over the coming years.

References 415

1.
Abbott CA, Garrow AP, Carrington AL, Morris J, Van Ross ER, Boulton AJ, North-West diabetes foot care s. Foot ulcer risk is lower in South-Asian and African-Caribbean compared with European diabetic patients in the U.K.: the North–West diabetes foot care study. Diabetes Care. 2005;28:1869-1875.
Not in our library10.2337/diacare.28.8.1869
2.
Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34:2220-2224.
Not in our library10.2337/dc11-1108
3.
Ahmad J. The diabetic foot. Diabetes Metab Syndr. 2016;10:48-60.
Not in our library10.1016/j.dsx.2015.04.002
4.
Aiyer R, Barkin RL, Bhatia A. Treatment of neuropathic pain with venlafaxine: a systematic review. Pain Med. 2017;18:1999-2012.
Not in our library10.1093/pm/pnw261
5.
Diagnostic utility of corneal confocal microscopy and intra-epidermal nerve fibre density in diabetic neuropathy · 2017
No notice
6.
Albers JW, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010;33:1090-1096.
Not in our library10.2337/dc09-1941
7.
Albrecht DS, et al. Neuroinflammation of the spinal cord and nerve roots in chronic radicular pain patients. Pain. 2018;159:968-977.
Not in our library10.1097/j.pain.0000000000001171
8.
Allegri M, Baron R, Hans G, Correa-Illanes G, Mayoral Rojals V, Mick G, Serpell M. A pharmacological treatment algorithm for localized neuropathic pain. Curr Med Res Opin. 2016;32(2):377-384.
Not in our library10.1185/03007995.2015.1129321
9.
Alleman CJ, Westerhout KY, Hensen M, Chambers C, Stoker M, Long S, van Nooten FE. Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: a review of the literature. Diabetes Res Clin Pract. 2015;109:215-225.
Not in our library10.1016/j.diabres.2015.04.031
10.
Ametov AS, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003;26:770-776.
Not in our library10.2337/diacare.26.3.770
11.
Amir R, et al. The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain. 2006;7:S1-29.
Not in our library10.1016/j.jpain.2006.01.444
12.
Andersson C, Guttorp P, Sarkka A. Discovering early diabetic neuropathy from epidermal nerve fiber patterns. Stat Med. 2016;35:4427-4442.
Not in our library10.1002/sim.7009
13.
Andersen ST, et al. Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected Type 2 diabetes followed for 13 years: ADDITION-Denmark. Diabetes Care. 2018;41:1068-1075.
Not in our library10.2337/dc17-2062
14.
Apfel SC, et al. Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. J Neurol Sci. 2001;189:3-5.
Not in our library10.1016/s0022-510x(01)00584-6
15.
Archer AG, Roberts VC, Watkins PJ. Blood flow patterns in painful diabetic neuropathy. Diabetologia. 1984;27:563-567.
Not in our library10.1007/bf00276968
16.
Attal N, Fermanian C, Fermanian J, Lanteri-Minet M, Alchaar H, Bouhassira D. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? Pain. 2008;138:343-353.
Not in our library10.1016/j.pain.2008.01.006
17.
Attal N, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-e1188.
Not in our library10.1111/j.1468-1331.2010.02999.x
18.
Attal N, et al. Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Eur J Pain. 2011;15:441-443.
Not in our library10.1016/j.ejpain.2011.03.005
19.
Attal N, Bouhassira D. Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? Pain. 2015;156(Suppl 1):S104-14.
Not in our library10.1097/01.j.pain.0000460358.01998.15
20.
Attal N, Bouhassira D, Baron R. Diagnosis and assessment of neuropathic pain through questionnaires. Lancet Neurol. 2018;17:456-466.
Not in our library10.1016/s1474-4422(18)30071-1
21.
Backonja MM, Coe CL, Muller DA, Schell K. Altered cytokine levels in the blood and cerebrospinal fluid of chronic pain patients. J Neuroimmunol. 2008;195:157-163.
Not in our library10.1016/j.jneuroim.2008.01.005
22.
Backonja MM, et al. Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. Pain. 2013;154:1807-1819.
Not in our library10.1016/j.pain.2013.05.047
23.
Backryd E, Lind AL, Thulin M, Larsson A, Gerdle B, Gordh T. High levels of cerebrospinal fluid chemokines point to the presence of neuroinflammation in peripheral neuropathic pain: a cross-sectional study of 2 cohorts of patients compared with healthy controls. Pain. 2017;158:2487-2495.
Not in our library10.1097/j.pain.0000000000001061
24.
Balasubramanyan S, Stemkowski PL, Stebbing MJ, Smith PA. Sciatic chronic constriction injury produces cell-type-specific changes in the electrophysiological properties of rat substantia gelatinosa neurons. J Neurophysiol. 2006;96:579-590.
Not in our library10.1152/jn.00087.2006
25.
Barbosa M, Saavedra A, Severo M, Maier C, Carvalho D. Validation and reliability of the portuguese version of the Michigan neuropathy screening instrument. Pain Pract. 2017;17:514-521.
Not in our library10.1111/papr.12479
26.
Baron R. Mechanisms of disease: neuropathic pain—a clinical perspective. Nat Clin Pract Neurol. 2006;2:95-106.
Not in our library10.1038/ncpneuro0113
27.
Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9:807-819.
Not in our library10.1016/s1474-4422(10)70143-5
28.
Baron R, Forster M, Binder A. Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach. Lancet Neurol. 2012;11:999-1005.
Not in our library10.1016/s1474-4422(12)70189-8
29.
Baron R, et al. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain. 2017;158:261-272.
Not in our library10.1097/j.pain.0000000000000753
30.
Bastyr EJ, Price KL, Bril V, Group MS. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther. 2005;27:1278-1294.
Not in our library10.1016/j.clinthera.2005.08.002
31.
Bee LA, Dickenson AH. Descending facilitation from the brainstem determines behavioural and neuronal hypersensitivity following nerve injury and efficacy of pregabalin. Pain. 2008;140:209-223.
Not in our library10.1016/j.pain.2008.08.008
32.
Beggs S, Salter MW. Stereological and somatotopic analysis of the spinal microglial response to peripheral nerve injury. Brain Behav Immun. 2007;21:624-633.
Not in our library10.1016/j.bbi.2006.10.017
33.
Belfer I, Dai F. Phenotyping and genotyping neuropathic pain. Curr Pain Headache Rep. 2010;14:203-212.
Not in our library10.1007/s11916-010-0110-1
34.
Bennett DL, Woods CG. Painful and painless channelopathies. Lancet Neurol. 2014;13:587-599.
Not in our library10.1016/s1474-4422(14)70024-9
35.
Bernier LP, Ase AR, Seguela P. P2X receptor channels in chronic pain pathways. Br J Pharmacol. 2018;175:2219-2230.
Not in our library10.1111/bph.13957
36.
Bierhaus A, et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med. 2012;18:926-933.
Not in our library10.1038/nm.2750
37.
Binder A. Human surrogate models of neuropathic pain: validity and limitations. Pain. 2016;157(Suppl 1):S48-52.
Not in our library10.1097/j.pain.0000000000000460
38.
Blesneac I, et al. Rare NaV1.7 variants associated with painful diabetic peripheral neuropathy. Pain. 2018;159:469-480.
Not in our library10.1097/j.pain.0000000000001116
39.
Borsook D, Kussman BD, George E, Becerra LR, Burke DW. Surgically induced neuropathic pain: understanding the perioperative process. Ann Surg. 2013;257:403-412.
Not in our library10.1097/sla.0b013e3182701a7b
40.
Bosma RL, et al. Brain dynamics and temporal summation of pain predicts neuropathic pain relief from ketamine infusion. Anesthesiology. 2018;129:1015-1024.
Not in our library10.1097/aln.0000000000002417
41.
Bouhassira D, Attal N. Diagnosis and assessment of neuropathic pain: the saga of clinical tools. Pain. 2011;152:S74-83.
Not in our library10.1016/j.pain.2010.11.027
42.
Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, Rostaing S, Lanteri-Minet M, Collin E, Grisart J, Boureau F. Development and validation of the neuropathic pain symptom. Inventory Pain. 2004;108(3):248-257.
Not in our library10.1016/j.pain.2003.12.024
43.
Bouhassira D, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114:29-36.
Not in our library10.1016/j.pain.2004.12.010
44.
Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain wih neuropathic characteristics in the general population. Pain. 2008;136:S380-387.
Not in our library10.1016/j.pain.2007.08.013
45.
Chronic Pain with Neuropathic Characteristics in Diabetic Patients: A French Cross-Sectional Study · 2013
No notice
46.
Bouhassira D, et al. Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: data from the randomized, double-blind, COMBO-DN study. Pain. 2014;155:2171-2179.
Not in our library10.1016/j.pain.2014.08.020
47.
Boulton AJ. The diabetic foot—an update. Foot Ankle Surg. 2008;14:120-124.
Not in our library10.1016/j.fas.2008.05.004
48.
Bril V, Perkins BA. Validation of the Toronto Clinical Scoring system for diabetic polyneuropathy. Diabetes Care. 2002;25:2048-2052.
Not in our library10.2337/diacare.25.11.2048
49.
Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy · 2009
No notice
50.
Bril V, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76:1758-1765.
Not in our library10.1212/wnl.0b013e3182166ebe
51.
Brown JJ, Pribesh SL, Baskette KG, Vinik AI, Colberg SR. A comparison of screening tools for the early detection of peripheral neuropathy in adults with and without type 2 diabetes. J Diabetes Res. 2017;2017:1467213.
Not in our library10.1155/2017/1467213
52.
Burke D, Fullen BM, Stokes D, Lennon O. Neuropathic pain prevalence following spinal cord injury: a systematic review and meta-analysis. Eur J Pain. 2017;21:29-44.
Not in our library10.1002/ejp.905
53.
Busserolles J, Tsantoulas C, Eschalier A, Lopez Garcia JA. Potassium channels in neuropathic pain: advances, challenges, and emerging ideas. Pain. 2016;157(Suppl 1):S7-14.
Not in our library10.1097/j.pain.0000000000000368
54.
Callaghan BC, Cheng HLT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11:521-534.
Not in our library10.1016/s1474-4422(12)70065-0
55.
Callaghan BC, Little AA, Feldman EL, Hughes RAC. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012.
Not in our library10.1002/14651858.cd007543.pub2
56.
Calles-Escandon J, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010;33:721-727.
Not in our library10.2337/dc09-1471
57.
Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001;44:1973-1988.
Not in our library10.1007/s001250100001
58.
Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006;52:77-92.
Not in our library10.1016/j.neuron.2006.09.021
59.
Campbell CM, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain. 2012;153:1815-1823.
Not in our library10.1016/j.pain.2012.04.014
60.
Caselli A, Rich J, Hanane T, Uccioli L, Veves A. Role of C-nociceptive fibers in the nerve axon reflex-related vasodilation in diabetes. Neurology. 2003;60:297-300.
Not in our library10.1212/01.wnl.0000040250.31755.f9
61.
Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389:816-824.
Not in our library10.1038/39807
62.
Challa SR. Surgical animal models of neuropathic pain: Pros and Cons. Int J Neurosci. 2015;125:170-174.
Not in our library10.3109/00207454.2014.922559
63.
Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev. 2007.
Not in our library10.1002/14651858.cd004572.pub2
64.
Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012.
Not in our library10.1002/14651858.cd008943.pub2
65.
Chaplan SR, et al. Neuronal hyperpolarization-activated pacemaker channels drive neuropathic pain. J Neurosci. 2003;23:1169-1178.
Not in our library10.1523/jneurosci.23-04-01169.2003
66.
Cheliout-Heraut F, et al. Exploration of small fibers for testing diabetic neuropathies. Jt Bone Spine. 2005;72:412-415.
Not in our library10.1016/j.jbspin.2004.10.003
67.
Chen L, Huang LY. Protein kinase C reduces Mg2+ block of NMDA-receptor channels as a mechanism of modulation. Nature. 1992;356:521-523.
Not in our library10.1038/356521a0
68.
Chen J, et al. The alpha2delta-1-NMDA receptor complex is critically involved in neuropathic pain development and gabapentin therapeutic actions. Cell Rep. 2018;22:2307-2321.
Not in our library10.1016/j.celrep.2018.02.021
69.
Cheng HT, et al. Increased axonal regeneration and swellings in intraepidermal nerve fibers characterize painful phenotypes of diabetic neuropathy. J Pain. 2013;14:941-947.
Not in our library10.1016/j.jpain.2013.03.005
70.
Choi SR, et al. Spinal D-serine increases PKC-dependent GluN1 phosphorylation contributing to the sigma-1 receptor-induced development of mechanical allodynia in a mouse model of neuropathic pain. J Pain. 2017;18:415-427.
Not in our library10.1016/j.jpain.2016.12.002
71.
Clark AK, Malcangio M. Microglial signalling mechanisms: cathepsin S and fractalkine. Exp Neurol. 2012;234:283-292.
Not in our library10.1016/j.expneurol.2011.09.012
72.
Fractalkine/CX3CR1 signaling during neuropathic pain · 2014
No notice
73.
Colleoni M, Sacerdote P. Murine models of human neuropathic pain. Biochem Biophys Acta. 2010;1802:924-933.
Not in our library10.1016/j.bbadis.2009.10.012
74.
Colloca L, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002.
Not in our library10.1038/nrdp.2017.2
75.
Collins SL, Moore RA, McQuayHj WP. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manag. 2000;20:449-458.
Not in our library10.1016/s0885-3924(00)00218-9
76.
Cooper TE, et al. Morphine for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;5:CD011669.
Not in our library10.1002/14651858.cd011669.pub2
77.
Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T. Total neuropathy score: validation and reliability study. Neurology. 1999;53:1660-1664.
Not in our library10.1212/wnl.53.8.1660
78.
Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1-32.
Not in our library10.1146/annurev.neuro.051508.135531
79.
Coull JA, et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature. 2005;438:1017-1021.
Not in our library10.1038/nature04223
80.
Coward K, et al. Immunolocalization of SNS/PN3 and NaN/SNS2 sodium channels in human pain states. Pain. 2000;85:41-50.
Not in our library10.1016/s0304-3959(99)00251-1
81.
Cox JJ, et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 2006;444:894-898.
Not in our library10.1038/nature05413
82.
Crawford B, Bouhassira D, Wong A, Dukes E. Conceptual adequacy of the neuropathic pain symptom inventory in six countries. Health Qual Life Outcomes. 2008;18(6):62.
Not in our library10.1186/1477-7525-6-62
83.
Cruccu G, Truini A. Sensory profiles: a new strategy for selecting patients in treatment trials for neuropathic pain. Pain. 2009;146:5-6.
Not in our library10.1016/j.pain.2009.07.004
84.
Cruccu G, Truini A. A review of neuropathic pain: from guidelines to clinical practice. Pain Ther. 2017;6:35-42.
Not in our library10.1007/s40122-017-0087-0
85.
Cruccu G, et al. Recommendations for the clinical use of somatosensory-evoked potentials. Clin Neurophysiol. 2008;119:1705-1719.
Not in our library10.1016/j.clinph.2008.03.016
86.
Cruccu G, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol. 2010;17:1010-1018.
Not in our library10.1111/j.1468-1331.2010.02969.x
87.
Cruccu G, et al. Trigeminal neuralgia: new classification and diagnostic grading for practice and research. Neurology. 2016;87:220-228.
Not in our library10.1212/wnl.0000000000002840
88.
Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: implications for mechanisms of pain. Pain. 2007;131:243-257.
Not in our library10.1016/j.pain.2007.07.026
89.
Curtin CM, Kenney D, Suarez P, Hentz VR, Hernandez-Boussard T, Mackey S, Carroll IR. A double-blind placebo randomized controlled trial of minocycline to reduce pain after carpal tunnel and trigger finger release. J Hand Surg Am. 2017;42:166-174.
Not in our library10.1016/j.jhsa.2016.12.011
90.
Davis KD, et al. Brain imaging tests for chronic pain: medical, legal and ethical issues and recommendations. Nat Rev Neurol. 2017;13:624-638.
Not in our library10.1038/nrneurol.2017.122
91.
De Keyser R, van den Broeke EN, Courtin A, Dufour A, Mouraux A. Event-related brain potentials elicited by high-speed cooling of the skin: a robust and non-painful method to assess the spinothalamic system in humans. Clin Neurophysiol. 2018;129:1011-1019.
Not in our library10.1016/j.clinph.2018.02.123
92.
Delpont B, Blanc C, Osseby GV, Hervieu-Begue M, Giroud M, Bejot Y. Pain after stroke: a review. Rev Neurol (Paris). 2018;174:671-674.
Not in our library10.1016/j.neurol.2017.11.011
93.
Demant DT, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain. 2014;155:2263-2273.
Not in our library10.1016/j.pain.2014.08.014
94.
Deng Y, Luo L, Hu Y, Fang K, Liu J. Clinical practice guidelines for the management of neuropathic pain: a systematic review. BMC Anesthesiol. 2016;16:12.
Not in our library10.1186/s12871-015-0150-5
95.
Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;1:CD011669.
Not in our library10.1002/14651858.cd007393.pub4
96.
Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1:CD007076.
Not in our library10.1002/14651858.cd007076.pub3
97.
Devigili G, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008;131:1912-1925.
Not in our library10.1093/brain/awn093
98.
Devor M. Ectopic discharge in Abeta afferents as a source of neuropathic pain. Exp Brain Res. 2009;196:115-128.
Not in our library10.1007/s00221-009-1724-6
99.
Dewanjee S, et al. Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets. Eur J Pharmacol. 2018;833:472-523.
Not in our library10.1016/j.ejphar.2018.06.034
100.
Di Stefano G, et al. Diagnostic accuracy of laser-evoked potentials in diabetic neuropathy. Pain. 2017;158:1100-1107.
Not in our library10.1097/j.pain.0000000000000889
101.
Dib-Hajj SD, Cummins TR, Black JA, Waxman SG. Sodium channels in normal and pathological pain. Annu Rev Neurosci. 2010;33:325-347.
Not in our library10.1146/annurev-neuro-060909-153234
102.
Doth AH, Hansson PT, Jensen MP, Taylor RS. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain. 2010;149:338-344.
Not in our library10.1016/j.pain.2010.02.034
103.
Drdla-Schutting R, Benrath J, Wunderbaldinger G, Sandkuhler J. Erasure of a spinal memory trace of pain by a brief, high-dose opioid administration. Science (New York, NY). 2012;335:235-238.
Not in our library10.1126/science.1211726
104.
Dull MM, et al. Methylglyoxal causes pain and hyperalgesia in human through C-fiber activation. Pain. 2019.
Not in our library10.1097/j.pain.0000000000001644
105.
Duehmke RM, Derry S, Wiffen PJ, Bell RF, Aldington D, Moore RA. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD011669.
Not in our library10.1002/14651858.cd003726.pub4
106.
Dworkin RH, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237-251.
Not in our library10.1016/j.pain.2007.08.033
107.
Dworkin RH, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85:S3-14.
Not in our library10.4065/mcp.2009.0649
108.
Dworkin RH, et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain. 2013;154:2249-2261.
Not in our library10.1016/j.pain.2013.06.004
109.
Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve. 1988;11:21-32.
Not in our library10.1002/mus.880110106
110.
Dyck PJ, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol. 1980;8:590-596.
Not in our library10.1002/ana.410080608
111.
Dyck PJ, Karnes JL, O'Brien PC, Litchy WJ, Low PA, Melton LJ. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology. 1992;42:1164-1170.
Not in our library10.1212/wnl.42.6.1164
112.
Dyck PJ, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817-824.
Not in our library10.1212/wnl.43.4.817
113.
Dyck PJ, et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs NPhys trial. Muscle Nerve. 2010;42:157-164.
Not in our library10.1002/mus.21661
114.
Dyck PJ, Carter RE, Litchy WJ. Modeling nerve conduction criteria for diagnosis of diabetic polyneuropathy. Muscle Nerve. 2011;44:340-345.
Not in our library10.1002/mus.22074
115.
Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacol Ther. 2008;120:1-34.
Not in our library10.1016/j.pharmthera.2008.05.005
116.
Edwards RR, et al. Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain. 2016;157:1851-1871.
Not in our library10.1097/j.pain.0000000000000602
117.
Ellis RJ, et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol. 2010;67:552-558.
Not in our library10.1001/archneurol.2010.76
118.
England JD, et al. Distal symmetrical polyneuropathy: a definition for clinical research. A report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Arch Phys Med Rehabil. 2005;86:167-174.
Not in our library10.1016/j.apmr.2004.09.011
119.
Epping R, Verhagen AP, Hoebink EA, Rooker S, Scholten-Peeters GGM. The diagnostic accuracy and test–retest reliability of the Dutch PainDETECT and the DN4 screening tools for neuropathic pain in patients with suspected cervical or lumbar radiculopathy. Musculoskelet Sci Pract. 2017;30:72-79.
Not in our library10.1016/j.msksp.2017.05.010
120.
Estacion M, et al. NaV1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. J Neurosci. 2008;28:11079-11088.
Not in our library10.1523/jneurosci.3443-08.2008
121.
European Medicines Agency. EMA/CHMP/970057/2011: guideline on the clinical development of medicinal products intended for the treatment of pain. https://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/12/WC500219131.pdf. Accessed 15 Sep 2019
Not in our library
122.
Ezenwa M, Yao Y, Suarez M, Zhao Z, Carrasco J, Angulo V, Shuey D, Roach K, Wang Z, Molokie R, Wilkie D. (187) Normative values for quantitative sensory testing in African Americans. J Pain. 2016;17:4.
Not in our library10.1016/j.jpain.2016.01.090
123.
Farooqi MA, et al. Validation of cooling detection threshold as a marker of sensorimotor polyneuropathy in type 2 diabetes. J Diabetes Complications. 2016;30:716-722.
Not in our library10.1016/j.jdiacomp.2015.12.023
124.
Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17:1281-1289.
Not in our library10.2337/diacare.17.11.1281
125.
Feldman EL, Nave KA, Jensen TS, Bennett DLH. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron. 2017;93:1296-1313.
Not in our library10.1016/j.neuron.2017.02.005
126.
Feldman EL, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5:41.
Not in our library10.1038/s41572-019-0092-1
127.
Fernyhough P. Mitochondrial dysfunction in diabetic neuropathy: a series of unfortunate metabolic events. Curr DiabRep. 2015;15:89.
Not in our library10.1007/s11892-015-0671-9
128.
Fernyhough P, McGavock J. Mechanisms of disease: mitochondrial dysfunction in sensory neuropathy and other complications in diabetes. Handb Clin Neurol. 2014;126:353-377.
Not in our library10.1016/b978-0-444-53480-4.00027-8
129.
Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis. 1998;5:209-227.
Not in our library10.1006/nbdi.1998.0204
130.
Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150:573-581.
Not in our library10.1016/j.pain.2010.06.019
131.
Finnerup NB, et al. Neuropathic pain needs systematic classification. Eur J Pain. 2013;17:953-956.
Not in our library10.1002/j.1532-2149.2012.00282.x
132.
Finnerup NB, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162-173.
Not in our library10.1016/s1474-4422(14)70251-0
133.
Neuropathic pain: an updated grading system for research and clinical practice · 2016
No notice
134.
Foley PL, et al. Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis. Pain. 2013;154:632-642.
Not in our library10.1016/j.pain.2012.12.002
135.
Forbes HJ, Thomas SL, Smeeth L, Clayton T, Farmer R, Bhaskaran K, Langan SM. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain. 2016;157:30-54.
Not in our library10.1097/j.pain.0000000000000307
136.
Forstenpointner J, Otto J, Baron R. Individualized neuropathic pain therapy based on phenotyping: are we there yet? Pain. 2018;159:569-575.
Not in our library10.1097/j.pain.0000000000001088
137.
Frazier WA, Angeletti RH, Bradshaw RA. Nerve growth factor and insulin. Science (New York, NY). 1972;176:482-488.
Not in our library10.1126/science.176.4034.482
138.
Freo U, Romualdi P, Kress HG. Tapentadol for neuropathic pain: a review of clinical studies. J Pain Res. 2019;12:1537-1551.
Not in our library10.2147/jpr.s190162
139.
Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005;115:254-263.
Not in our library10.1016/j.pain.2005.02.032
140.
Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22:1911-1920.
Not in our library10.1185/030079906x132488
141.
Freynhagen R, et al. Current understanding of the mixed pain concept: a brief narrative review. Curr Med Res Opin. 2019;35:1011-1018.
Not in our library10.1080/03007995.2018.1552042
142.
Fukuoka M, Sakurai K, Ohta T, Kiyoki M, Katayama I. Tacalcitol, an active vitamin D3, induces nerve growth factor production in human epidermal keratinocytes. Skin Pharmacol Appl Skin Physiol. 2001;14:226-233.
Not in our library10.1159/000056351
143.
Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014.
Not in our library10.1002/14651858.cd009122.pub2
144.
Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015.
Not in our library10.1002/14651858.cd011091.pub2
145.
Gao F, Zheng ZM. Animal models of diabetic neuropathic pain. Exp Clin Endocrinol Diabetes. 2014;122:100-106.
Not in our library10.1055/s-0033-1363234
146.
Gasparotti R, Padua L, Briani C, Lauria G. New technologies for the assessment of neuropathies. Nat Rev Neurol. 2017;13:203-216.
Not in our library10.1038/nrneurol.2017.31
147.
German National Disease Management Guideline for Diabetic Neuropathy: Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftli-chen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Neuropathie bei Diabetes im Erwachsenenalter—Langfassung, 1. Auflage. Version 5. 2011. www.dm-neuropathie.versorgungsleitlinien.de. Accessed 17 Sep 2019.
Not in our library10.6101/azq/000302
148.
Gibbons CH. Treatment-induced neuropathy of diabetes. Curr Diab Rep. 2017;17:127.
Not in our library10.1007/s11892-017-0960-6
149.
Gibbons CH. Treatment induced neuropathy of diabetes—long term implications in type 1 diabetes. J Diabetes Complications. 2017;31:715-720.
Not in our library10.1016/j.jdiacomp.2017.01.010
150.
Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain. 2015;138:43-52.
Not in our library10.1093/brain/awu307
151.
Gierthmuhlen J, Baron R. Neuropathic pain. Semin Neurol. 2016;36:462-468.
Not in our library10.1055/s-0036-1584950
152.
Gierthmühlen J, Maier C, Baron R, Tölle T, Treede RD, Birbaumer N, Huge V, Koroschetz J, Krumova EK, Lauchart M, Maihöfner C, Richter H, Westermann A, DFNS Study Group. Sensory signs in complex regional pain syndrome and peripheral nerve injury. Pain. 2012;153:765-774.
Not in our library10.1016/j.pain.2011.11.009
153.
Gilron I, Jensen TS, Dickenson AH. Combination pharmacotherapy for management of chronic pain: from bench to bedside. Lancet Neurol. 2013;12(11):1084-1095.
Not in our library10.1016/s1474-4422(13)70193-5
154.
Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology. 2003;60:927-934.
Not in our library10.1212/01.wnl.0000057720.36503.2c
155.
Gold MS, Gebhart GF. Nociceptor sensitization in pain pathogenesis. Nat Med. 2010;16:1248-1257.
Not in our library10.1038/nm.2235
156.
Gold MS, Reichling DB, Shuster MJ, Levine JD. Hyperalgesic agents increase a tetrodotoxin-resistant Na+ current in nociceptors. Proc Natl Acad Sci USA. 1996;93(3):1108-1112.
Not in our library10.1073/pnas.93.3.1108
157.
Gonzalez-Duarte A, Lem-Carrillo M, Guerrero-Torres L. Normative values of quantitative sensory testing in Hispanic Latino population. Brain Behav. 2016;6:e00466.
Not in our library10.1002/brb3.466
158.
Goodman CW, Brett AS. Gabapentin and Pregabalin for pain—is increased prescribing a cause for concern? N Engl J Med. 2017;377:411-414.
Not in our library10.1056/nejmp1704633
159.
Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manag. 2005;30:374-385.
Not in our library10.1016/j.jpainsymman.2005.04.009
160.
Gracely RH, Lynch SA, Bennett GJ. Painful neuropathy: altered central processing maintained dynamically by peripheral input. Pain. 1992;51:175-194.
Not in our library10.1016/0304-3959(92)90259-e
161.
Granovsky Y. Conditioned pain modulation: a predictor for development and treatment of neuropathic pain. Curr Pain Headache Rep. 2013;17:361.
Not in our library10.1007/s11916-013-0361-8
162.
Efficient conditioned pain modulation despite pain persistence in painful diabetic neuropathy · 2017
Not checked
163.
Gregory NS, Harris AL, Robinson CR, Dougherty PM, Fuchs PN, Sluka KA. An overview of animal models of pain: disease models and outcome measures. J Pain. 2013;14:1255-1269.
Not in our library10.1016/j.jpain.2013.06.008
164.
Grewal AS, Bhardwaj S, Pandita D, Lather V, Sekhon BS. Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases. Mini Rev Med Chem. 2016;16:120-162.
Not in our library10.2174/1389557515666150909143737
165.
Grote CW, Wright DE. A role for insulin in diabetic neuropathy. Front Neurosci. 2016;10:581.
Not in our library10.3389/fnins.2016.00581
166.
Gruber-Schoffnegger D, Drdla-Schutting R, Honigsperger C, Wunderbaldinger G, Gassner M, Sandkuhler J. Induction of thermal hyperalgesia and synaptic long-term potentiation in the spinal cord lamina I by TNF-alpha and IL-1beta is mediated by glial cells. J Neurosci. 2013;33:6540-6551.
Not in our library10.1523/jneurosci.5087-12.2013
167.
Haanpaa ML, Backonja MM, Bennett MI, Bouhassira D, Cruccu G, Hansson PT, Jensen TS, Kauppila T, Rice ASC, Smith BH, Treede RD, Baron R. Assessment of neuropathic pain in primary care. Am J Med. 2009;122:S13-S21.
Not in our library10.1016/j.amjmed.2009.04.006
168.
Haanpaa M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011;152:14-27.
Not in our library10.1016/j.pain.2010.07.031
169.
Hains BC, Waxman SG. Sodium channel expression and the molecular pathophysiology of pain after SCI. Prog Brain Res. 2007;161:195-203.
Not in our library10.1016/s0079-6123(06)61013-3
170.
Hameed S. Nav1.7 and Nav1.8: role in the pathophysiology of pain. Mol Pain. 2019;15:1744806919858801.
Not in our library10.1177/1744806919858801
171.
Hansson P. Neuropathic pain: clinical characteristics and diagnostic workup. Eur J Pain. 2002;6(Suppl A):47-50.
Not in our library10.1053/eujp.2001.0322
172.
Haroutounian S, Nikolajsen L, Bendtsen TF, Finnerup NB, Kristensen AD, Hasselstrom JB, Jensen TS. Primary afferent input critical for maintaining spontaneous pain in peripheral neuropathy. Pain. 2014;155:1272-1279.
Not in our library10.1016/j.pain.2014.03.022
173.
Hatch MN, Cushing TR, Carlson GD, Chang EY. Neuropathic pain and SCI: identification and treatment strategies in the 21st century. J Neurol Sci. 2018;384:75-83.
Not in our library10.1016/j.jns.2017.11.018
174.
Hearn L, Derry S, Phillips T, Moore RA, Wiffen PJ. Imipramine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014.
Not in our library10.1002/14651858.cd010769.pub2
175.
Hearn L, Moore RA, Derry S, Wiffen PJ, Phillips T. Desipramine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014.
Not in our library10.1002/14651858.cd011003.pub2
176.
Hebert HL, Veluchamy A, Torrance N, Smith BH. Risk factors for neuropathic pain in diabetes mellitus. Pain. 2017;158:560-568.
Not in our library10.1097/j.pain.0000000000000785
177.
Herder C, et al. Proinflammatory cytokines predict the incidence and progression of distal sensorimotor polyneuropathy: KORA F4/FF4 study. Diabetes Care. 2017;40:569-576.
Not in our library10.2337/dc16-2259
178.
Hildebrand ME, et al. Potentiation of synaptic GluN2B NMDAR currents by Fyn kinase is gated through BDNF-mediated disinhibition in spinal pain processing. Cell Rep. 2016;17:2753-2765.
Not in our library10.1016/j.celrep.2016.11.024
179.
Hirayasu K, et al. Difference in normal limit values of nerve conduction parameters between Westerners and Japanese people might need to be considered when diagnosing diabetic polyneuropathy using a Point-of-Care Sural Nerve Conduction Device (NC-stat(R)/DPNCheck). J Diabetes Investig. 2018;9:1173-1181.
Not in our library10.1111/jdi.12818
180.
Hoeijmakers JG, Faber CG, Merkies IS, Waxman SG. Painful peripheral neuropathy and sodium channel mutations. Neurosci Lett. 2015;596:51-59.
Not in our library10.1016/j.neulet.2014.12.056
181.
Hoffmann T, Kistner K, Carr RW, Nassar MA, Reeh PW, Weidner C. Reduced excitability and impaired nociception in peripheral unmyelinated fibers from Nav1.9-null mice. Pain. 2017;158:58-67.
Not in our library10.1097/j.pain.0000000000000723
182.
Holiner I, et al. Validity of the neurological examination in diagnosing diabetic peripheral neuropathy. Pediatr Neurol. 2013;49:171-177.
Not in our library10.1016/j.pediatrneurol.2013.03.014
183.
Hsieh ST. Pathology and functional diagnosis of small-fiber painful neuropathy. Acta Neurol Taiwan. 2010;19:82-89.
Not in our library
184.
Huang Q, Chen Y, Gong N, Wang YX. Methylglyoxal mediates streptozotocin-induced diabetic neuropathic pain via activation of the peripheral TRPA1 and Nav1.8 channels. Metab Clin Exp. 2016;65:463-474.
Not in our library10.1016/j.metabol.2015.12.002
185.
Hwang YT, Davies G. 'Insulin neuritis' to 'treatment-induced neuropathy of diabetes': new name, same mystery. Pract Neurol. 2016;16:53-55.
Not in our library10.1136/practneurol-2015-001215
186.
IASP (2011) Part III: Pain terms. A current list with definitions and notes on usage. International Association for the Study of Pain (IASP). Pain terms. https://www.iasp-pain.org/terminology. Accessed 15 Mar 2019
Not in our library
187.
IDF Diabetes Atlas, 8th ed. https://www.diabetesatlas.org/across-the-globe.html. Accessed 30 Oct 2019
Not in our library
188.
Inoue K. Purinergic signaling in microglia in the pathogenesis of neuropathic pain. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93:174-182.
Not in our library10.2183/pjab.93.011
189.
Inoue K, Tsuda M. Microglia in neuropathic pain: cellular and molecular mechanisms and therapeutic potential. Nat Rev Neurosci. 2018;19:138-152.
Not in our library10.1038/nrn.2018.2
190.
Inyang KE, Szabo-Pardi T, Wentworth E, McDougal TA, Dussor G, Burton MD, Price TJ. The antidiabetic drug metformin prevents and reverses neuropathic pain and spinal cord microglial activation in male but not female mice. Pharmacol Res. 2019;139:1-16.
Not in our library10.1016/j.phrs.2018.10.027
191.
Ismail-Beigi F, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419-430.
Not in our library10.1016/s0140-6736(10)60576-4
192.
Jaggi AS, Jain V, Singh N. Animal models of neuropathic pain. Fundam Clin Pharmacol. 2011;25:1-28.
Not in our library10.1111/j.1472-8206.2009.00801.x
193.
Jain R, Jain S, Raison CL, Maletic V. Painful diabetic neuropathy is more than pain alone: examining the role of anxiety and depression as mediators and complicators. Curr Diab Rep. 2011;11:275-284.
Not in our library10.1007/s11892-011-0202-2
194.
Jay GW, Barkin RL. Neuropathic pain: etiology, pathophysiology, mechanisms, and evaluations. Dis Mon. 2014;60:6-47.
Not in our library10.1016/j.disamonth.2013.12.001
195.
Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. Lancet Neurol. 2014;13:924-935.
Not in our library10.1016/s1474-4422(14)70102-4
196.
Jensen TS, Bach FW, Kastrup J, Dejgaard A, Brennum J. Vibratory and thermal thresholds in diabetics with and without clinical neuropathy. Acta Neurol Scand. 1991;84:326-333.
Not in our library10.1111/j.1600-0404.1991.tb04963.x
197.
Jensen TS, Madsen CS, Finnerup NB. Pharmacology and treatment of neuropathic pains. Curr Opin Neurol. 2009;22:467-474.
Not in our library10.1097/wco.0b013e3283311e13
198.
Jensen TS, Baron R, Haanpaa M, Kalso E, Loeser JD, Rice AS, Treede RD. A new definition of neuropathic pain. Pain. 2011;152:2204-2205.
Not in our library10.1016/j.pain.2011.06.017
199.
Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci. 2003;26:696-705.
Not in our library10.1016/j.tins.2003.09.017
200.
Ji RR, Berta T, Nedergaard M. Glia and pain: is chronic pain a gliopathy? Pain. 2013;154(Suppl 1):S10-28.
Not in our library10.1016/j.pain.2013.06.022
201.
Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and central sensitization in chronic and widespread pain. Anesthesiology. 2018;129:343-366.
Not in our library10.1097/aln.0000000000002130
202.
Jiang B, Zhang Y, Zhao J, She C, Zhou X, Dong Q, Wang P. Effects of localized X-ray irradiation on peripheral nerve regeneration in transected sciatic nerve in rats. Radiat Res. 2017;188:455-462.
Not in our library10.1667/rr14799.1
203.
Jin SX, Zhuang ZY, Woolf CJ, Ji RR. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci. 2003;23:4017-4022.
Not in our library10.1523/jneurosci.23-10-04017.2003
204.
Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA. 2003;290:1757-1762.
Not in our library10.1001/jama.290.13.1757
205.
Kavitha KV, Tiwari S, Purandare VB, Khedkar S, Bhosale SS, Unnikrishnan AG. Choice of wound care in diabetic foot ulcer: a practical approach. World J Diabetes. 2014;5:546-556.
Not in our library10.4239/wjd.v5.i4.546
206.
Transformation of the Output of Spinal Lamina I Neurons After Nerve Injury and Microglia Stimulation Underlying Neuropathic Pain · 2007
No notice
207.
Kennedy DL, Kemp HI, Ridout D, Yarnitsky D, Rice AS. Reliability of conditioned pain modulation: a systematic review. Pain. 2016;157:2410-2419.
Not in our library10.1097/j.pain.0000000000000689
208.
Khangura RK, Sharma J, Bali A, Singh N, Jaggi AS. An integrated review on new targets in the treatment of neuropathic pain. Korean J Physiol Pharmacol. 2019;23:1-20.
Not in our library10.4196/kjpp.2019.23.1.1
209.
Kim SK, et al. Cortical astrocytes rewire somatosensory cortical circuits for peripheral neuropathic pain. J Clin Investig. 2016;126:1983-1997.
Not in our library10.1172/jci82859
210.
Klein T, Magerl W, Hopf HC, Sandkuhler J, Treede RD. Perceptual correlates of nociceptive long-term potentiation and long-term depression in humans. J Neurosci. 2004;24:964-971.
Not in our library10.1523/jneurosci.1222-03.2004
211.
Klein T, Magerl W, Rolke R, Treede RD. Human surrogate models of neuropathic pain. Pain. 2005;115:227-233.
Not in our library10.1016/j.pain.2005.03.021
212.
Kobayashi M, Zochodne DW. Diabetic neuropathy and the sensory neuron: new aspects of pathogenesis and their treatment implications. J Diabetes Investig. 2018;9:1239-1254.
Not in our library10.1111/jdi.12833
213.
Kopf S, et al. Deep phenotyping neuropathy: an underestimated complication in patients with pre-diabetes and type 2 diabetes associated with albuminuria. Diabetes Res Clin Pract. 2018;146:191-201.
Not in our library10.1016/j.diabres.2018.10.020
214.
Kosek E, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016;157:1382-1386.
Not in our library10.1097/j.pain.0000000000000507
215.
Kotani N, et al. Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of postherpetic neuralgia. Am J Med. 2004;116:318-324.
Not in our library10.1016/j.amjmed.2003.10.027
216.
Krause SJ, Backonja MM. Development of a neuropathic pain questionnaire. Clin J Pain. 2003;19:306-314.
Not in our library10.1097/00002508-200309000-00004
217.
Krishnan ST, Rayman G. The LDIflare: a novel test of C-fiber function demonstrates early neuropathy in type 2 diabetes. Diabetes Care. 2004;27:2930-2935.
Not in our library10.2337/diacare.27.12.2930
218.
Lacagnina MJ, Watkins LR, Grace PM. Toll-like receptors and their role in persistent pain. Pharmacol Ther. 2018;184:145-158.
Not in our library10.1016/j.pharmthera.2017.10.006
219.
La Cesa S, et al. How to diagnose neuropathic pain? The contribution from clinical examination, pain questionnaires and diagnostic tests. Neurol Sci. 2015;36:2169-2175.
Not in our library10.1007/s10072-015-2382-z
220.
Lai J, Hunter JC, Porreca F. The role of voltage-gated sodium channels in neuropathic pain. Curr Opin Neurobiol. 2003;13:291-297.
Not in our library10.1016/s0959-4388(03)00074-6
221.
Lai J, Porreca F, Hunter JC, Gold MS. Voltage-gated sodium channels and hyperalgesia. Annu Rev Pharmacol Toxicol. 2004;44:371-397.
Not in our library10.1146/annurev.pharmtox.44.101802.121627
222.
Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, Karter AJ. The legacy effect in Type 2 diabetes: impact of early glycemic control on future complications (the diabetes and aging study). Diabetes Care. 2019;42:416-426.
Not in our library10.2337/dc17-1144
223.
Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10:895-926.
Not in our library10.1016/j.jpain.2009.06.012
224.
Lauria G, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2010;17:903-912, e944–909.
Not in our library10.1111/j.1468-1331.2010.03023.x
225.
Leone C, et al. Cooling the skin for assessing small-fibre function. Pain. 2019;160:1967-1975.
Not in our library10.1097/j.pain.0000000000001584
226.
Lenz FA, Kwan HC, Martin R, Tasker R, Richardson RT, Dostrovsky JO. Characteristics of somatotopic organization and spontaneous neuronal activity in the region of the thalamic principal sensory nucleus in patients with spinal cord transection. J Neurophysiol. 1994;72:1570-1587.
Not in our library10.1152/jn.1994.72.4.1570
227.
Liyanage PL, Lekamwasam S, Weerarathna TP. Validity of the Diabetic Neuropathy Score and Diabetic Neuropathy Examination score as screening tools for the detection of distal symmetrical diabetic neuropathy. J Diabetes. 2012;4:264-265.
Not in our library10.1111/j.1753-0407.2012.00201.x
228.
Loeser JD, Treede RD. The Kyoto protocol of IASP basic pain terminology. Pain. 2008;137:473-477.
Not in our library10.1016/j.pain.2008.04.025
229.
Love S. An experimental study of peripheral nerve regeneration after x-irradiation. Brain. 1983;106(Pt 1):39-54.
Not in our library10.1093/brain/106.1.39
230.
Low PA, Singer W. Treatment-induced neuropathy of diabetes: an energy crisis? Brain. 2015;138:2-3.
Not in our library10.1093/brain/awu327
231.
Lu WY, Xiong ZG, Lei S, Orser BA, Dudek E, Browning MD, MacDonald JF. G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. Nat Neurosci. 1999;2:331-338.
Not in our library10.1038/7243
232.
Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014.
Not in our library10.1002/14651858.cd007115.pub3
233.
Luo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, Williams ME, Yaksh TL. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci. 2001;21:1868-1875.
Not in our library10.1523/jneurosci.21-06-01868.2001
234.
Lucchetta M, Pazzaglia C, Padua L, Briani C. Exploring neuropathic symptoms in a large cohort of Italian patients with different peripheral nervous system diseases. Neurol Sci. 2011;32(3):423-426.
Not in our library10.1007/s10072-011-0498-3
235.
Magerl W, Krumova EK, Baron R, Tolle T, Treede RD, Maier C. Reference data for quantitative sensory testing (QST): refined stratification for age and a novel method for statistical comparison of group data. Pain. 2010;151:598-605.
Not in our library10.1016/j.pain.2010.07.026
236.
Magrinelli F, et al. The association between serum cytokines and damage to large and small nerve fibers in diabetic peripheral neuropathy. J Diabetes Res. 2015;2015:547834.
Not in our library10.1155/2015/547834
237.
Malik RA, et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia. 2005;48:578-585.
Not in our library10.1007/s00125-004-1663-5
238.
Mallick-Searle T, Snodgrass B, Brant JM. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology. J Multidiscip Healthc. 2016;9:447-454.
Not in our library10.2147/jmdh.s106340
239.
Manchikanti L, Singh V. Managing phantom pain. Pain Phys. 2004;7:365-375.
Not in our library
240.
Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005;6:521-532.
Not in our library10.1038/nrn1700
241.
Margolis RB, Tait RC, Krause SJ. A rating system for use with patient pain drawings. Pain. 1986;24:57-65.
Not in our library10.1016/0304-3959(86)90026-6
242.
Martin MM. Diabetic neuropathy; a clinical study of 150 cases. Brain. 1953;76:594-624.
Not in our library10.1093/brain/76.4.594
243.
Martinez V, et al. The efficacy of a glial inhibitor, minocycline, for preventing persistent pain after lumbar discectomy: a randomized, double-blind, controlled study. Pain. 2013;154:1197-1203.
Not in our library10.1016/j.pain.2013.03.028
244.
Mathieson S, Maher CG, Terwee CB, Folly de Campos T, Lin CW. Neuropathic pain screening questionnaires have limited measurement properties. A systematic review. J Clin Epidemiol. 2015;68:957-966.
Not in our library10.1016/j.jclinepi.2015.03.010
245.
Max MB. Towards physiologically based treatment of patients with neuropathic pain. Pain. 1990;42:131-137.
Not in our library10.1016/0304-3959(90)91156-d
246.
May A. Chronic pain may change the structure of the brain. Pain. 2008;137:7-15.
Not in our library10.1016/j.pain.2008.02.034
247.
McMahon SB, Malcangio M. Current challenges in glia-pain biology. Neuron. 2009;64:46-54.
Not in our library10.1016/j.neuron.2009.09.033
248.
Meacham K, Shepherd A, Mohapatra DP, Haroutounian S. Neuropathic pain: central vs. peripheral mechanisms. Curr Pain Headache Rep. 2017;21:28.
Not in our library10.1007/s11916-017-0629-5
249.
Mehra S, Tavakoli M, Kallinikos PA, Efron N, Boulton AJ, Augustine T, Malik RA. Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care. 2007;30:2608-2612.
Not in our library10.2337/dc07-0870
250.
Meijer JW, van Sonderen E, Blaauwwiekel EE, Smit AJ, Groothoff JW, Eisma WH, Links TP. Diabetic neuropathy examination: a hierarchical scoring system to diagnose distal polyneuropathy in diabetes. Diabetes Care. 2000;23:750-753.
Not in our library10.2337/diacare.23.6.750
251.
Meijer JW, Smit AJ, Sonderen EV, Groothoff JW, Eisma WH, Links TP. Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the Diabetic Neuropathy Symptom score. Diabet Med. 2002;19:962-965.
Not in our library10.1046/j.1464-5491.2002.00819.x
252.
Meijer JW, et al. Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptom and diabetic neuropathy examination scores. Diabetes Care. 2003;26:697-701.
Not in our library10.2337/diacare.26.3.697
253.
Meijer JW, Smit AJ, Lefrandt JD, van der Hoeven JH, Hoogenberg K, Links TP. Back to basics in diagnosing diabetic polyneuropathy with the tuning fork! Diabetes Care. 2005;28:2201-2205.
Not in our library10.2337/diacare.28.9.2201
254.
Meng H, Johnston B, Englesakis M, Moulin DE, Bhatia A. Selective cannabinoids for chronic neuropathic pain: a systematic review and meta-analysis. Anesth Analg. 2017;125:1638-1652.
Not in our library10.1213/ane.0000000000002110
255.
Mick G, Baron R, Finnerup NB, Hans G, Kern KU, Brett B, Dworkin RH. What is localized neuropathic pain? A first proposal to characterize and define a widely used term. Pain Manag. 2011.
Not in our library10.2217/pmt.11.77
256.
Mickle AD, Shepherd AJ, Mohapatra DP. Sensory TRP channels: the key transducers of nociception and pain. Progress Mol Biol Transl Sci. 2015;131:73-118.
Not in our library10.1016/bs.pmbts.2015.01.002
257.
Mickle AD, Shepherd AJ, Mohapatra DP. Nociceptive TRP channels: sensory detectors and transducers in multiple pain pathologies. Pharmaceuticals (Basel, Switzerland). 2016.
Not in our library10.3390/ph9040072
258.
Mika J. Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol Rep. 2008;60:297-307.
Not in our library
259.
Milligan ED, Sloane EM, Watkins LR. Glia in pathological pain: a role for fractalkine. J Neuroimmunol. 2008;198:113-120.
Not in our library10.1016/j.jneuroim.2008.04.011
260.
Minett MS, Falk S, Santana-Varela S, Bogdanov YD, Nassar MA, Heegaard AM, Wood JN. Pain without nociceptors? Nav1.7-independent pain mechanisms. Cell Rep. 2014;6:301-312.
Not in our library10.1016/j.celrep.2013.12.033
261.
Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006;108:477-481.
Not in our library10.1016/j.clineuro.2005.08.003
262.
Moisset X, Bouhassira D. Brain imaging of neuropathic pain. NeuroImage. 2007;37(Suppl 1):S80-88.
Not in our library10.1016/j.neuroimage.2007.03.054
263.
Moore KA, Kohno T, Karchewski LA, Scholz J, Baba H, Woolf CJ. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci. 2002;22:6724-6731.
Not in our library10.1523/jneurosci.22-15-06724.2002
264.
Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014.
Not in our library10.1002/14651858.cd007938.pub3
265.
Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015.
Not in our library10.1002/14651858.cd008242.pub3
266.
Moulin D, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19:328-335.
Not in our library10.1155/2014/754693
267.
Nardelli P, Khan J, Powers R, Cope TC, Rich MM. Reduced motoneuron excitability in a rat model of sepsis. J Neurophysiol. 2013;109:1775-1781.
Not in our library10.1152/jn.00936.2012
268.
Nawroth PP, et al. The quest for more research on painful diabetic neuropathy. Neuroscience. 2018;387:28-37.
Not in our library10.1016/j.neuroscience.2017.09.023
269.
Nebuchennykh M, Loseth S, Lindal S, Mellgren SI. The value of skin biopsy with recording of intraepidermal nerve fiber density and quantitative sensory testing in the assessment of small fiber involvement in patients with different causes of polyneuropathy. J Neurol. 2009;256:1067-1075.
Not in our library10.1007/s00415-009-5065-y
270.
Ni HD, et al. Glial activation in the periaqueductal gray promotes descending facilitation of neuropathic pain through the p38 MAPK signaling pathway. J Neurosci Res. 2016;94:50-61.
Not in our library10.1002/jnr.23672
271.
NICE (2013) Clinical guideline: neuropathic pain-pharmacological management. https://guidance.nice.org.uk/CG173. Accessed July 15 2019
Not in our library
272.
North RY, et al. Electrophysiological and transcriptomic correlates of neuropathic pain in human dorsal root ganglion neurons. Brain. 2019;142:1215-1226.
Not in our library10.1093/brain/awz063
273.
Nugraha B, et al. The IASP classification of chronic pain for ICD-11: functioning properties of chronic pain. Pain. 2019;160:88-94.
Not in our library10.1097/j.pain.0000000000001433
274.
O'Brien PD, Sakowski SA, Feldman EL. Mouse models of diabetic neuropath. ILAR J. 2014;54:259-272.
Not in our library10.1093/ilar/ilt052
275.
Olaleye D, Perkins BA, Bril V. Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. Diabetes Res Clin Pract. 2001;54:115-128.
Not in our library10.1016/s0168-8227(01)00278-9
276.
Pantalone KM, et al. Effect of glycemic control on the Diabetes Complications Severity Index score and development of complications in people with newly diagnosed type 2 diabetes. J Diabetes. 2018;10:192-199.
Not in our library10.1111/1753-0407.12613
277.
Papanas N, Ziegler D. Efficacy of alpha-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother. 2014;15:2721-2731.
Not in our library10.1517/14656566.2014.972935
278.
Botulinum Toxin for the Treatment of Neuropathic Pain · 2017
No notice
279.
Pascal MMV, et al. DOLORisk: study protocol for a multi-centre observational study to understand the risk factors and determinants of neuropathic pain. Wellcome Open Res. 2018;3:63.
Not in our library10.12688/wellcomeopenres.14576.2
280.
Patel R, Dickenson AH. Neuronal hyperexcitability in the ventral posterior thalamus of neuropathic rats: modality selective effects of pregabalin. J Neurophysiol. 2016;116:159-170.
Not in our library10.1152/jn.00237.2016
281.
Peltier A, Goutman SA, Callaghan BC. Painful diabetic neuropathy. BMJ. 2014;348:g1799.
Not in our library10.1136/bmj.g1799
282.
Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care. 2001;24:250-256.
Not in our library10.2337/diacare.24.2.250
283.
Pfau DB, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): reference data for the trunk and application in patients with chronic postherpetic neuralgia. Pain. 2014;155:1002-1015.
Not in our library10.1016/j.pain.2014.02.004
284.
Pinzur MS, Slovenkai MP, Trepman E, Shields NN, Diabetes Committee of American Orthopaedic F, Ankle S. Guidelines for diabetic foot care: recommendations endorsed by the Diabetes Committee of the American Orthopaedic Foot and Ankle Society. Foot Ankle Int. 2005;26:113-119.
Not in our library10.1177/107110070502600112
285.
Ponirakis G, et al. The diagnostic accuracy of Neuropad for assessing large and small fibre diabetic neuropathy. Diabet Med. 2014;31:1673-1680.
Not in our library10.1111/dme.12536
286.
Ponirakis G, et al. NerveCheck: an inexpensive quantitative sensory testing device for patients with diabetic neuropathy. Diabetes Res Clin Pract. 2016;113:101-107.
Not in our library10.1016/j.diabres.2015.12.023
287.
Pop-Busui R, et al. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). Cohort Diabetes care. 2013;36:3208-3215.
Not in our library10.2337/dc13-0012
288.
Pop-Busui R, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40:136-154.
Not in our library10.2337/dc16-2042
289.
Prabodha LBL, Sirisena ND, Dissanayake VHW. Susceptible and prognostic genetic factors associated with diabetic peripheral neuropathy: a comprehensive literature review. Int J Endocrinol. 2018;2018:8641942.
Not in our library10.1155/2018/8641942
290.
Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA, Clinical Guidelines Committee of the American College of P. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians. Ann Intern Med. 2018;168:569-576.
Not in our library10.7326/m17-0939
291.
Quattrini C, et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes. 2007;56:2148-2154.
Not in our library10.2337/db07-0285
292.
Quattrini C, Jeziorska M, Boulton AJ, Malik RA. Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy. Diabetes Care. 2008;31:140-145.
Not in our library10.2337/dc07-1556
293.
Raghavendra V, Tanga F, DeLeo JA. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther. 2003;306:624-630.
Not in our library10.1124/jpet.103.052407
294.
Rahman M, Griffin SJ, Rathmann W, Wareham NJ. How should peripheral neuropathy be assessed in people with diabetes in primary care? A population-based comparison of four measures. Diabet Med. 2003;20:368-374.
Not in our library10.1046/j.1464-5491.2003.00931.x
295.
Rahman W, D'Mello R, Dickenson AH. Peripheral nerve injury-induced changes in spinal alpha(2)-adrenoceptor-mediated modulation of mechanically evoked dorsal horn neuronal responses. J Pain. 2008;9:350-359.
Not in our library10.1016/j.jpain.2007.11.010
296.
Raputova J, et al. Sensory phenotype and risk factors for painful diabetic neuropathy: a cross-sectional observational study. Pain. 2017;158:2340-2353.
Not in our library10.1097/j.pain.0000000000001034
297.
Rauck RL, Shaibani A, Biton V, Simpson J, Koch B. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain. 2007;23:150-158.
Not in our library10.1097/01.ajp.0000210957.39621.b2
298.
Ren K, Dubner R. Interactions between the immune and nervous systems in pain. Nat Med. 2010;16:1267-1276.
Not in our library10.1038/nm.2234
299.
Rice AS, Smith BH, Blyth FM. Pain and the global burden of disease. Pain. 2016;157:791-796.
Not in our library10.1097/j.pain.0000000000000454
300.
Rodriguez-Gutierrez R, Lipska KJ, McCoy RG. Intensive glycemic control in type 2 diabetes mellitus—a balancing act of latent benefit and avoidable harm: a teachable moment. JAMA Intern Med. 2016;176:300-301.
Not in our library10.1001/jamainternmed.2015.8320
301.
Rolke R, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain. 2006;123:231-243.
Not in our library10.1016/j.pain.2006.01.041
302.
Roth T, van Seventer R, Murphy TK. The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials. Curr Med Res Opin. 2010;26:2411-2419.
Not in our library10.1185/03007995.2010.516142
303.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007.
Not in our library10.1002/14651858.cd005454.pub2
304.
Sadosky A, Mardekian J, Parsons B, Hopps M, Bienen EJ, Markman J. Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy. J Diabetes Complicat. 2015;29:212-217.
Not in our library10.1016/j.jdiacomp.2014.10.013
305.
Safarpour Y, Jabbari B. Botulinum toxin treatment of pain syndromes—an evidence based review. Toxicon. 2018;147:120-128.
Not in our library10.1016/j.toxicon.2018.01.017
306.
Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nat Med. 2017;23:1018-1027.
Not in our library10.1038/nm.4397
307.
Sanchez-Ramirez GM, Caram-Salas NL, Rocha-Gonzalez HI, Vidal-Cantu GC, Medina-Santillan R, Reyes-Garcia G, Granados-Soto V. Benfotiamine relieves inflammatory and neuropathic pain in rats. Eur J Pharmacol. 2006;530:48-53.
Not in our library10.1016/j.ejphar.2005.11.016
308.
Understanding LTP in Pain Pathways · 2007
No notice
309.
Sartor CD, Oliveira MD, Campos V, Ferreira J, Sacco ICN. Cross-cultural adaptation and measurement properties of the Brazilian Version of the Michigan Neuropathy Screening Instrument. Braz J Phys Ther. 2018;22:222-230.
Not in our library10.1016/j.bjpt.2017.10.004
310.
Schafers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci. 2003;23:2517-2521.
Not in our library10.1523/jneurosci.23-07-02517.2003
311.
Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci. 2007;10:1361-1368.
Not in our library10.1038/nn1992
312.
Scholz J, et al. Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury. J Neurosci. 2005;25:7317-7323.
Not in our library10.1523/jneurosci.1526-05.2005
313.
Scholz J, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019;160:53-59.
Not in our library10.1097/j.pain.0000000000001365
314.
Schratzberger P, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Investig. 2001;107:1083-1092.
Not in our library10.1172/jci12188
315.
Schreiber AK, Nones CF, Reis RC, Chichorro JG, Cunha JM. Diabetic neuropathic pain: physiopathology and treatment. World J Diabetes. 2015;6:432-444.
Not in our library10.4239/wjd.v6.i3.432
316.
Schuh-Hofer S, Fischer J, Unterberg A, Treede RD, Ahmadi R. Spinal cord stimulation modulates descending pain inhibition and temporal summation of pricking pain in patients with neuropathic pain. Acta Neurochir. 2018;160:2509-2519.
Not in our library10.1007/s00701-018-3669-7
317.
Schwartz S, et al. A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy. Clin Drug Investig. 2015;35:95-108.
Not in our library10.1007/s40261-014-0249-3
318.
Selvarajah D, Awadh M, Gandhi R, Wilkinson ID, Tesfaye S. Alterations in somatomotor network functional connectivity in painful diabetic neuropathy—a resting state functional magnetic resonance imaging study. Diabetes. 2018.
Not in our library10.2337/db18-61-or
319.
Selvarajah D, Heiberg-Gibbons F, Wilkinson ID, Gandhi R, Tesfaye S. A magnetic resonance imaging volumetry study of regional brain atrophy in diabetic peripheral neuropathy. Diabetes. 2018.
Not in our library10.2337/db18-550-p
320.
Serra J, et al. Microneurographic identification of spontaneous activity in C-nociceptors in neuropathic pain states in humans and rats. Pain. 2012;153:42-55.
Not in our library10.1016/j.pain.2011.08.015
321.
Shen FY, et al. Alleviation of neuropathic pain by regulating T-type calcium channels in rat anterior cingulate cortex. Mol Pain. 2015;11:7.
Not in our library10.1186/s12990-015-0008-3
322.
Nerve and Vascular Biomarkers in Skin Biopsies Differentiate Painful From Painless Peripheral Neuropathy in Type 2 Diabetes · 2021
Not checked
323.
Shillo P, et al. Reduced vitamin D levels in painful diabetic peripheral neuropathy. Diabetic Med J Br Diabetic Assoc. 2019;36:44-51.
Not in our library10.1111/dme.13798
324.
Shillo PR, Selvarajah D, Greig M, Rao GD, Edden RAE, Wilkinson ID, Tesfaye S. Painless diabetic peripheral neuropathy is characterised by reduced thalamic gamma-aminobutyric acid (GABA). Diabetic Med. 2016;33:15-16.
Not in our library10.1111/dme.5_13047
325.
Shun CT, et al. Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments. Brain. 2004;127:1593-1605.
Not in our library10.1093/brain/awh180
326.
Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol. 2014;18:1-14.
Not in our library10.4196/kjpp.2014.18.1.1
327.
Sloan G, et al. A new look at painful diabetic neuropathy. Diabetes Res Clin Pract. 2018;144:177-191.
Not in our library10.1016/j.diabres.2018.08.020
328.
Smith BH, Torrance N. Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep. 2012;16:191-198.
Not in our library10.1007/s11916-012-0256-0
329.
Snyder MJ, Gibbs LM, Lindsay TJ. Treating painful diabetic peripheral neuropathy: an update. Am Fam Physician. 2016;94:227-234.
Not in our library
330.
Sorensen L, Molyneaux L, Yue DK. The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diabetes Care. 2006;29:883-887.
Not in our library10.2337/diacare.29.04.06.dc05-2180
331.
Sorge RE, et al. Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nat Neurosci. 2015;18:1081-1083.
Not in our library10.1038/nn.4053
332.
Spallone V. Might genetics play a role in understanding and treating diabetic polyneuropathy? Diabetes Metab Res Rev. 2017.
Not in our library10.1002/dmrr.2882
333.
Spallone V, Morganti R, D'Amato C, Greco C, Cacciotti L, Marfia GA. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabet Med. 2012;29:578-585.
Not in our library10.1111/j.1464-5491.2011.03500.x
334.
Advances in understanding nociception and neuropathic pain · 2017
No notice
335.
Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010;123:S3-11.
Not in our library10.1016/j.amjmed.2009.12.004
336.
Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. 2008;116:600-605.
Not in our library10.1055/s-2008-1065351
337.
Sumitani M, Ueda H, Hozumi J, Inoue R, Kogure T, Yamada Y, Kogure T. Minocycline does not decrease intensity of neuropathic pain intensity, but does improve its affective dimension. J Pain Palliate Care Pharmacother. 2016;30:31-35.
Not in our library10.3109/15360288.2014.1003674
338.
Sullivan KA, Lentz SI, Roberts JL, Feldman EL. Criteria for creating and assessing mouse models of diabetic neuropathy. Curr Drug Targets. 2008;9:3-13.
Not in our library10.2174/138945008783431763
339.
Sun C, et al. IL-17 contributed to the neuropathic pain following peripheral nerve injury by promoting astrocyte proliferation and secretion of proinflammatory cytokines. Mol Med Rep. 2017;15:89-96.
Not in our library10.3892/mmr.2016.6018
340.
Tampin B, Briffa NK, Goucke R, Slater H. Identification of neuropathic pain in patients with neck/upper limb pain: application of a grading system and screening tools. Pain. 2013;154(12):2813-2822.
Not in our library10.1016/j.pain.2013.08.018
341.
Tan T, Barry P, Reken S, Baker M, Guideline Development G. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ. 2010;340:c1079.
Not in our library10.1136/bmj.c1079
342.
Tandrup T, Woolf CJ, Coggeshall RE. Delayed loss of small dorsal root ganglion cells after transection of the rat sciatic nerve. J Comp Neurol. 2000;422:172-180.
Not in our library10.1002/(sici)1096-9861(20000626)422:2<172::aid-cne2>3.0.co;2-h
343.
Taylor AM, Mehrabani S, Liu S, Taylor AJ, Cahill CM. Topography of microglial activation in sensory- and affect-related brain regions in chronic pain. J Neurosci Res. 2017;95:1330-1335.
Not in our library10.1002/jnr.23883
344.
Tappe-Theodor A, Kuner R. Studying ongoing and spontaneous pain in rodents—challenges and opportunities. Eur J Neurosci. 2014;39:1881-1890.
Not in our library10.1111/ejn.12643
345.
Tesfaye S, Harris ND, Wilson RM, Ward JD. Exercise-induced conduction velocity increment: a marker of impaired peripheral nerve blood flow in diabetic neuropathy. Diabetologia. 1992;35:155-159.
Not in our library10.1007/bf00402548
346.
Tesfaye S, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352:341-350.
Not in our library10.1056/nejmoa032782
347.
Tesfaye S, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285-2293.
Not in our library10.2337/dc10-1303
348.
Tesfaye S, Selvarajah D, Gandhi R, Greig M, Shillo P, Fang F, Wilkinson ID. Diabetic peripheral neuropathy may not be as its name suggests: evidence from magnetic resonance imaging. Pain. 2016;157(Suppl 1):S72-80.
Not in our library10.1097/j.pain.0000000000000465
349.
Thacker MA, et al. CCL2 is a key mediator of microglia activation in neuropathic pain states. Eur J Pain. 2009;13:263-272.
Not in our library10.1016/j.ejpain.2008.04.017
350.
Themistocleous AC, et al. The Pain in Neuropathy Study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy. Pain. 2016;157:1132-1145.
Not in our library10.1097/j.pain.0000000000000491
351.
Thrainsdottir S, et al. Endoneurial capillary abnormalities presage deterioration of glucose tolerance and accompany peripheral neuropathy in man. Diabetes. 2003;52:2615-2622.
Not in our library10.2337/diabetes.52.10.2615
352.
Investigating the validity of the DN4 in a consecutive population of patients with chronic pain. · 2017
Not checked
353.
Timmerman H, et al. Avoiding Catch-22: validating the PainDETECT in a population of patients with chronic pain. BMC Neurol. 2018;18:91.
Not in our library10.1186/s12883-018-1094-4
354.
Timmerman H, Wilder-Smith OH, Steegers MA, Vissers KC, Wolff AP. The added value of bedside examination and screening QST to improve neuropathic pain identification in patients with chronic pain. J Pain Res. 2018;11:1307-1318.
Not in our library10.2147/jpr.s154698
355.
Torrance N, Elliott AM, Lee AJ, Smith BH. Severe chronic pain is associated with increased 10 year mortality. A cohort record linkage study. Eur J Pain. 2010;14:380-386.
Not in our library10.1016/j.ejpain.2009.07.006
356.
Neuropathic pain in the community: More under-treated than refractory? · 2013
No notice
357.
Tracy JA, Dyck PJ. The spectrum of diabetic neuropathies. Phys Med Rehabil Clin N Am. 2008;19(1–26):v.
Not in our library10.1016/j.pmr.2007.10.010
358.
Treede RD. The role of quantitative sensory testing in the prediction of chronic pain. Pain. 2019;160:S66-S69.
Not in our library10.1097/j.pain.0000000000001544
359.
Treede RD, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630-1635.
Not in our library10.1212/01.wnl.0000282763.29778.59
360.
Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, Cohen M, Evers S, Finnerup NB, First MB, Giamberardino MA, Kaasa S, Korwisi B, Kosek E, Lavandʼhomme P, Nicholas M, Perrot S, Scholz J, Schug S, Smith BH, Svensson P, Vlaeyen JWS, Wang SJ. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain. 2019;160:19-27.
Not in our library10.1097/j.pain.0000000000001384
361.
Trouvin AP, Perrot S, Lloret-Linares C. Efficacy of venlafaxine in neuropathic pain: a narrative review of optimized treatment. Clin Ther. 2017;39:1104-1122.
Not in our library10.1016/j.clinthera.2017.05.347
362.
Truini A, et al. Does the epidermal nerve fibre density measured by skin biopsy in patients with peripheral neuropathies correlate with neuropathic pain? Pain. 2014;155:828-832.
Not in our library10.1016/j.pain.2014.01.022
363.
Truini A, et al. A cross-sectional study investigating frequency and features of definitely diagnosed diabetic painful polyneuropathy. Pain. 2018;159:2658-2666.
Not in our library10.1097/j.pain.0000000000001378
364.
Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, Inoue K. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature. 2003;424:778-783.
Not in our library10.1038/nature01786
365.
Tsuda M, Inoue K, Salter MW. Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia. Trends Neurosci. 2005;28:101-107.
Not in our library10.1016/j.tins.2004.12.002
366.
Tuveson B, Leffler AS, Hansson P. Heterotopic noxious conditioning stimulation (HNCS) reduced the intensity of spontaneous pain, but not of allodynia in painful peripheral neuropathy. Eur J Pain. 2007;11:452-462.
Not in our library10.1016/j.ejpain.2006.06.007
367.
UKPSD Study Group U. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS). Group Lancet. 1998;352:837-853.
Not in our library10.1016/s0140-6736(98)07019-6
368.
United Nations (2019) Revision of world population prospects. https://population.un.org/wpp/. Accessed 12 07 2019
Not in our library
369.
Van Acker K, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab. 2009;35:206-213.
Not in our library10.1016/j.diabet.2008.11.004
370.
van den Born JC, Hammes HP, Greffrath W, van Goor H, Hillebrands JL. Gasotransmitters in vascular complications of diabetes. Diabetes. 2016;65:331-345.
Not in our library10.2337/db15-1003
371.
van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155:654-662.
Not in our library10.1016/j.pain.2013.11.013
372.
Vanelderen P, et al. Effect of minocycline on lumbar radicular neuropathic pain: a randomized, placebo-controlled, double-blind clinical trial with amitriptyline as a comparator. Anesthesiology. 2015;122:399-406.
Not in our library10.1097/aln.0000000000000508
373.
Vinik EJ, Hayes RP, Oglesby A, Bastyr E, Barlow P, Ford-Molvik SL, Vinik AI. The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 2005;7:497-508.
Not in our library10.1089/dia.2005.7.497
374.
Vinik A, Rosenstock J, Sharma U, Feins K, Hsu C, Merante D, Investigators D-AUUPIS. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014;37:3253-3261.
Not in our library10.2337/dc14-1044
375.
Vinik AI, et al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol. 2016;16:251.
Not in our library10.1186/s12883-016-0752-7
376.
Vlckova-Moravcova E, Bednarik J, Dusek L, Toyka KV, Sommer C. Diagnostic validity of epidermal nerve fiber densities in painful sensory neuropathies. Muscle Nerve. 2008;37:50-60.
Not in our library10.1002/mus.20889
377.
Vo T, Rice AS, Dworkin RH. Non-steroidal anti-inflammatory drugs for neuropathic pain: how do we explain continued widespread use? Pain. 2009;143:169-171.
Not in our library10.1016/j.pain.2009.03.013
378.
Vollert J, et al. Quantitative sensory testing using DFNS protocol in Europe: an evaluation of heterogeneity across multiple centers in patients with peripheral neuropathic pain and healthy subjects. Pain. 2016;157:750-758.
Not in our library10.1097/j.pain.0000000000000433
379.
Vollert J, et al. Pathophysiological mechanisms of neuropathic pain: comparison of sensory phenotypes in patients and human surrogate pain models. Pain. 2018;159:1090-1102.
Not in our library10.1097/j.pain.0000000000001190
380.
von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron. 2012;73:638-652.
Not in our library10.1016/j.neuron.2012.02.008
381.
Wall PD, Gutnick M. Ongoing activity in peripheral nerves: the physiology and pharmacology of impulses originating from a neuroma. Exp Neurol. 1974;43:580-593.
Not in our library10.1016/0014-4886(74)90197-6
382.
Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of inhaled cannabis on painful diabetic neuropathy. J Pain. 2015;16:616-627.
Not in our library10.1016/j.jpain.2015.03.008
383.
Wang H, et al. Fulranumab for treatment of diabetic peripheral neuropathic pain: a randomized controlled trial. Neurology. 2014;83:628-637.
Not in our library10.1212/wnl.0000000000000686
384.
Wang ZT, Yu G, Wang HS, Yi SP, Su RB, Gong ZH. Changes in VGLUT2 expression and function in pain-related supraspinal regions correlate with the pathogenesis of neuropathic pain in a mouse spared nerve injury model. Brain Res. 2015;1624:515-524.
Not in our library10.1016/j.brainres.2015.08.010
385.
Watanabe K, et al. Altered cerebral blood flow in the anterior cingulate cortex is associated with neuropathic pain. J Neurol Neurosurg Psychiatry. 2018;89:1082-1087.
Not in our library10.1136/jnnp-2017-316601
386.
Watson JC, Sandroni P. Central neuropathic pain syndromes. Mayo Clin Proc. 2016;91:372-385.
Not in our library10.1016/j.mayocp.2016.01.017
387.
Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105:71-78.
Not in our library10.1016/s0304-3959(03)00160-x
388.
Weintrob N, Amitay I, Lilos P, Shalitin S, Lazar L, Josefsberg Z. Bedside neuropathy disability score compared to quantitative sensory testing for measurement of diabetic neuropathy in children, adolescents, and young adults with type 1 diabetes. J Diabetes Complicat. 2007;21:13-19.
Not in our library10.1016/j.jdiacomp.2005.11.002
389.
Wiffen PJ, Derry S, Bell RF, Rice AS, Tolle TR, Phillips T, Moore RA. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD007938.
Not in our library10.1002/14651858.cd007938.pub4
390.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
Not in our library10.2337/diacare.27.5.1047
391.
Wolff RF, Bala MM, Westwood M, Kessels AG, Kleijnen J. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly. 2010;140:297-306.
Not in our library10.4414/smw.2010.12995
392.
Wood JN, Boorman JP, Okuse K, Baker MD. Voltage-gated sodium channels and pain pathways. J Neurobiol. 2004;61:55-71.
Not in our library10.1002/neu.20094
393.
Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science (New York, NY). 2000;288:1765-1769.
Not in our library10.1126/science.288.5472.1765
394.
Woolf CJ, Shortland P, Coggeshall RE. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature. 1992;355:75-78.
Not in our library10.1038/355075a0
395.
World Health Organization (2001) International classification of functioning, disability and health: ICF. World Health Organization, Geneva. ICD 11. https://icd.who.int/browse11/l-m/en. Accessed 15 Aug 2019
Not in our library
396.
Wymer JP, Simpson J, Sen D, Bongardt S, Lacosamide SPSG. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain. 2009;25:376-385.
Not in our library10.1097/ajp.0b013e318196d2b6
397.
Xanthos DN, Sandkuhler J. Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nat Rev Neurosci. 2014;15:43-53.
Not in our library10.1038/nrn3617
398.
Xiong Q, Lu B, Ye H, Wu X, Zhang T, Li Y. The diagnostic value of neuropathy symptom and change score, neuropathy impairment score and michigan neuropathy screening instrument for diabetic peripheral neuropathy. Eur Neurol. 2015;74:323-327.
Not in our library10.1159/000441449
399.
Yagihashi S, Mizukami H, Sugimoto K. Mechanism of diabetic neuropathy: where are we now and where to go? J Diabetes Investig. 2011;2:18-32.
Not in our library10.1111/j.2040-1124.2010.00070.x
400.
Yang XD, Fang PF, Xiang DX, Yang YY. Topical treatments for diabetic neuropathic pain. Exp Ther Med. 2019;17:1963-1976.
Not in our library10.3892/etm.2019.7173
401.
Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain. 2012;153:1193-1198.
Not in our library10.1016/j.pain.2012.02.021
402.
Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, Hu CJ. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72:1473-1478.
Not in our library10.1212/01.wnl.0000345968.05959.cf
403.
Zamponi GW, Lewis RJ, Todorovic SM, Arneric SP, Snutch TP. Role of voltage-gated calcium channels in ascending pain pathways. Brain Res Rev. 2009;60:84-89.
Not in our library10.1016/j.brainresrev.2008.12.021
404.
Zeilhofer HU, Wildner H, Yevenes GE. Fast synaptic inhibition in spinal sensory processing and pain control. Physiol Rev. 2012;92:193-235.
Not in our library10.1152/physrev.00043.2010
405.
Zelman DC, Gore M, Dukes E, Tai KS, Brandenburg N. Validation of a modified version of the Brief Pain Inventory for painful diabetic peripheral neuropathy. J Vasc Nurs. 2005;23:97-104.
Not in our library10.1016/j.jvn.2005.06.004
406.
Zhang J, Mense S, Treede RD, Hoheisel U. Prevention and reversal of latent sensitization of dorsal horn neurons by glial blockers in a model of low back pain in male rats. J Neurophysiol. 2017;118:2059-2069.
Not in our library10.1152/jn.00680.2016
407.
Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev. 2017;12:CD007963.
Not in our library10.1002/14651858.cd007963.pub3
408.
Zhuang ZY, Kawasaki Y, Tan PH, Wen YR, Huang J, Ji RR. Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine. Brain Behav Immun. 2007;21:642-651.
Not in our library10.1016/j.bbi.2006.11.003
409.
Ziegler D, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29:2365-2370.
Not in our library10.2337/dc06-1216
410.
Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care. 2009;32:1479-1484.
Not in our library10.2337/dc09-0545
411.
Ziegler D, Keller J, Maier C, Pannek J, German Diabetes A. Diabetic neuropathy. Exp Clin Endocrinol Diabetes. 2014;122:406-415.
Not in our library10.1055/s-0034-1366435
412.
Ziegler D, Landgraf R, Lobmann R, Reiners K, Rett K, Schnell O, Strom A. Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (PROTECT study). Diabetes Res Clin Pract. 2018;139:147-154.
Not in our library10.1016/j.diabres.2018.02.043
413.
Zin CS, Nissen LM, Smith MT, O'Callaghan JP, Moore BJ. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs. 2008;22:417-442.
Not in our library10.2165/00023210-200822050-00005
414.
Zorina-Lichtenwalter K, Parisien M, Diatchenko L. Genetic studies of human neuropathic pain conditions: a review. Pain. 2018;159:583-594.
Not in our library10.1097/j.pain.0000000000001099
415.
Zur E. Topical treatment of neuropathic pain using compounded medications. Clin J Pain. 2014;30:73-91.
Not in our library10.1097/ajp.0b013e318285d1ba

Cited by papers we hold 2

Progress on the Elucidation of the Antinociceptive Effect of Ginseng and Ginsenosides in Chronic Pain · 2022
Not checked
The Role of Oxidative Stress and Antioxidants in Diabetic Wound Healing · 2021
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.